US20070009954A1 - Parallel polymorphism scoring by amplification and error correction - Google Patents

Parallel polymorphism scoring by amplification and error correction Download PDF

Info

Publication number
US20070009954A1
US20070009954A1 US11/521,754 US52175406A US2007009954A1 US 20070009954 A1 US20070009954 A1 US 20070009954A1 US 52175406 A US52175406 A US 52175406A US 2007009954 A1 US2007009954 A1 US 2007009954A1
Authority
US
United States
Prior art keywords
polymerase
probe
labeled
query
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/521,754
Inventor
Yan Wang
Michael Finney
Fan CHEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bio Rad Laboratories Inc
Original Assignee
Bio Rad Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Rad Laboratories Inc filed Critical Bio Rad Laboratories Inc
Priority to US11/521,754 priority Critical patent/US20070009954A1/en
Publication of US20070009954A1 publication Critical patent/US20070009954A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/6858Allele-specific amplification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6816Hybridisation assays characterised by the detection means
    • C12Q1/6823Release of bound markers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/80Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869Methods for sequencing

Definitions

  • This invention provides a method of detecting polymorphisms, e.g., single nucleotide polymorphisms (SNPs) by amplification and error correction.
  • the invention encompasses methods of performing amplification and error correction using an improved generation of nucleic acid polymerases, and methods of multiplexing the assay.
  • the improvement to the polymerases is the joining of a sequence-non-specific nucleic-acid-binding domain to the enzyme in a manner that enhances the ability of the enzyme to bind and catalyticly modify the nucleic acid.
  • SNP Single Nucleotide Polymorphism
  • SNP scoring has been emphasized in the literature because it is the most difficult case, but most methods capable of scoring SNPs are also capable of scoring additional types of polymorphisms.
  • One of the known assays for detecting single-base differences in DNA samples uses an exonuclease specific for mismatched bases (see, e.g., U.S. Pat. No. 5,391,480).
  • an assay involves labeling the 3′ nucleotide in a primer with a fluorescent marker.
  • the labeled oligonucleotide is hybridized to an unknown DNA sample. If the 3′ nucleotide (the query position) of the oligonucleotide is complementary to the corresponding nucleotide in the hybridized DNA, it will be insensitive to nuclease; if there is a mismatch it will be sensitive to nuclease and will be cleaved.
  • the query position corresponds to the 3′ end of one of the two primers.
  • This primer is synthesized in two versions (1 and 2), one complementary to each of the two expected versions of a SNP (SNP versions 1 and 2, respectively).
  • SNP versions 1 and 2 are labeled with distinguishable fluors.
  • the polymerase used for the PCR is one capable of excising mismatched 3′ nucleotides (an “error-correcting” or “3′ exonuclease-activity-containing” polymerase).
  • primer 2 will at some frequency anneal to an amplicon containing SNP version 1 and the 3′ nucleotide will be clipped off by the error-correcting activity of the polymerase. Clipped-off fluorescent nucleotides are detected by a decrease in fluorescence polarization (FP).
  • primer 1 which is fully complementary to SNP version 1, will at some frequency anneal to an amplicon containing SNP version 1 and be extended to full amplicon length. The extended primer then becomes insensitive to further attack by nuclease.
  • polymerases such as Pfu are capable of extending a labeled nucleotide if it is correctly matched and clipping it if it is mismatched.
  • the procedure is also distinct from the “Taqman” assay (see, e.g., U.S. Pat. Nos. 5,210,015 and 5,487,972), which uses the 5′-3′ nuclease activity of some thermostable polymerases.
  • the prior art protocol is therefore conventionally performed by 1) pre-amplifying a region containing the SNP site using unlabeled primers and Taq or other polymerase capable of amplifying single copies, 2) purifying the amplified DNA, 3) re-amplifying with labeled primers and an error-correcting polymerase, and 4) detecting whether error correction has occurred.
  • the current invention meets the need for an economical SNP assay that can be performed using small amounts of genomic DNA.
  • an error-correction SNP assay capable of robust operation from small amounts of genomic DNA and several methods for parallelizing this assay for low-cost, high throughput operation.
  • the processivity of a polymerase i.e., the amount of product generated by the enzyme per binding event, can be enhanced by increasing the stability of the modifying enzyme/nucleic acid complex.
  • Co-pending U.S. application Ser. No. 09/870,353 and WO01/92501 disclose modified polymerases that have increased processivity that is achieved by joining a sequence-non-specific double-stranded nucleic acid binding domain to the enzyme, or its catalytic domain.
  • the modified polymerases disclosed are error-correcting Family B polymerases, which typically are used in the current invention.
  • a first method comprises: (a) contacting a target nucleic acid comprising a query sequence with a probe oligonucleotide under conditions in which the probe specifically hybridizes to the target nucleic acid, wherein the 3′ nucleotide of the probe is a labeled query nucleotide and the probe oligonucleotide is attached to a discrete surface location, e.g., in a microarray, by a linkage that does not include the 3′ nucleotide; (b) providing an error-correcting polymerase; (c) incubating the assay under conditions in which the probe is extended by the polymerase, wherein the labeled query nucleotide is cleaved from the probe when mismatched with the query sequence; and (d) detecting the amount of probe in the discrete location that has been cleaved.
  • a second method comprises: (a) contacting a target nucleic acid comprising a query sequence with a probe oligonucleotide under conditions in which the probe specifically hybridizes to the target nucleic acid, wherein the 3′ nucleotide of the probe is a labeled query nucleotide; (b) providing an error-correcting polymerase; (c) incubating the assay under conditions in which the probe is extended by the polymerase, wherein the labeled query nucleotide is cleaved from the probe when mismatched with the query sequence; (d) providing a capture oligonucleotide attached to a discrete location and complementary to the product of the extended probe; (e) allowing the product of the extended probe the opportunity to hybridize with the capture oligonucleotide; and (f) determining the amount of label associated with the discrete location.
  • a third method comprises: (a) contacting a target nucleic acid comprising at least two query sequences with at least two probe oligonucleotides under conditions in which the probes specifically hybridize to the target nucleic acid, wherein the 3′ nucleotides of the probes are labeled query nucleotides; (b) providing an error-correcting polymerase; (c) incubating the assay under conditions in which the probes are extended by the polymerase, wherein the labeled query nucleotides are cleaved from the probe when mismatched with the query sequences; (d) separating the products of the extended probes electrophoretically; and (e) determining the amount of label associated with the products of each extended probe.
  • a fourth method comprises: (a) contacting a target nucleic acid comprising a query sequence with a probe oligonucleotide under conditions in which the probe specifically hybridizes to the target nucleic acid, wherein the 3′ nucleotide of the probe is a labeled query nucleotide; (b) providing an error-correcting polymerase comprising at least two heterologous domains, wherein a first domain that is a sequence-non-specific nucleic-acid-binding domain is joined to a second domain that is a polymerase domain, wherein the sequence non-specific nucleic-acid-binding domain: (i) binds to double-stranded nucleic acid, and (ii) enhances the processivity of the polymerase compared to an identical polymerase not having the sequence non-specific nucleic-acid-binding domain fused to it; (c) incubating the assay under conditions in which the probe is extended by the polymerase, wherein the labeled query
  • the probe oligonucleotide is one of two primers in a polymerase chain reaction.
  • the target nucleic acid can be obtained using a PCR performed with two unlabeled primers, wherein the query sequence is not present in either of the two primers; and further, wherein the PCR reaction is contacted with the probe oligonucleotide during amplification.
  • the 3′ query nucleotide can also be labeled with a quencher.
  • the oligonucleotide probe can be complementary to a region in the amplicon that does not comprise the two primers. Additionally, the method can be performed using with a second probe oligonucleotide. The method of claim 1 , further comprising a second probe oligonucleotide.
  • the 3′ end label of the assay can be labeled with a fluorescent label and the extended product is then assayed for incorporation of the fluorescent label.
  • the 3′ end can also be labeled with a fluorescent quenching molecule and the extended product can be assayed for loss of the quencher.
  • the extended product can be detected by electrophoresis and determining the presence of a fluorescent band corresponding to the extended product.
  • FIG. 1 shows an agarose gel of reaction products from an assay that shows that the error-correcting enzymes Pfu and PfS efficiently correct mismatched labeled bases during PCR amplification.
  • FIG. 2 shows fluorescent intensity traces (electropherograms) for Taq and PfS reactions.
  • Enhances in the context of an enzyme refers to improving the activity of the enzyme, e.g., increasing the amount of product per unit enzyme per unit time.
  • Heterologous when used with reference to portions of a protein, indicates that the protein comprises two or more domains that are not found in the same relationship to each other in nature.
  • a protein e.g., a fusion protein, contains two or more domains from unrelated proteins arranged to make a new functional protein.
  • “Join” refers to any method known in the art for functionally connecting protein domains, including without limitation recombinant fusion with or without intervening domains, intein-mediated fusion, non-covalent association, and covalent bonding, including disulfide bonding; hydrogen bonding; electrostatic bonding; and conformational bonding, e.g., antibody-antigen, and biotin-avidin associations.
  • a “polymerase” can include an entire enzyme or a catalytic domain.
  • An “improved polymerase” includes a sequence-non-specific double-stranded DNA binding domain joined to the polymerase or polymerase domain.
  • An “unimproved polymerase” or “unmodified polymerase” is a polymerase that does not have a sequence-non-specific double-stranded DNA binding domain. “Improved polymerases” are described, for example in WO01/92501.
  • Domain refers to a unit of a protein or protein complex, comprising a polypeptide subsequence, a complete polypeptide sequence, or a plurality of polypeptide sequences where that unit has a defined function.
  • the function is understood to be broadly defined and can be ligand binding, catalytic activity or can have a stabilizing effect on the structure of the protein.
  • Error-correcting activity of a polymerase or polymerase domain refers to the 3′ to 5′ exonuclease proofreading activity of a template-specific nucleic acid polymerase whereby nucleotides that do not form Watson-Crick base pairs with the template are removed from the 3′ end of an oligonucleotide, i.e., a strand being synthesized from a template, in a sequential manner.
  • polymerases that have error-correcting activity include polymerases from Pryococcus furiosus, Thermococcus litoralis , and Thermotoga maritima.
  • Processivity refers to the ability of a nucleic acid modifying enzyme to remain attached to the template or substrate and perform multiple modification reactions. Typically “processivity” refers to the number of reactions catalyzed per binding event.
  • Sequence-non-specific nucleic-acid-binding domain refers to a protein domain which binds with significant affinity to a nucleic acid, for which there is no known nucleic acid which binds to the protein domain with more than 100-fold more affinity than another nucleic acid with the same nucleotide composition but a different nucleotide sequence.
  • Thermally stable polymerase refers to any enzyme that catalyzes polynucleotide synthesis by addition of nucleotide units to a nucleotide chain using DNA or RNA as a template and has an optimal activity at a temperature above 45° C.
  • amplification reaction refers to any in vitro means for multiplying the copies of a target sequence of nucleic acid. Such methods include but are not limited to polymerase (PCR), DNA ligase, (LCR), Q ⁇ RNA replicase, and RNA transcription-based (TAS and 3SR) amplification reactions.
  • PCR polymerase
  • LCR DNA ligase
  • TAS and 3SR RNA transcription-based amplification reactions.
  • “Amplifying” refers to a step of submitting a solution to conditions sufficient to allow for amplification of a polynucleotide if all of the components of the reaction are intact.
  • Components of an amplification reaction include, e.g., primers, a polynucleotide template, polymerase, nucleotides, and the like.
  • the term “amplifying” typically refers to an “exponential” increase in target nucleic acid. However, “amplifying” as used herein can also refer to linear increases in the numbers of a select target sequence of nucleic acid.
  • amplification reaction mixture refers to an aqueous solution comprising the various reagents used to amplify a target nucleic acid. These include enzymes, aqueous buffers, salts, amplification primers, target nucleic acid, and nucleoside triphosphates. Depending upon the context, the mixture can be either a complete or incomplete amplification reaction mixture
  • PCR Polymerase chain reaction
  • PCR refers to a method whereby a specific segment or subsequence of a target double-stranded DNA, is amplified in a geometric progression.
  • PCR is well known to those of skill in the art; see, e.g., U.S. Pat. Nos. 4,683,195 and 4,683,202; and PCR Protocols: A Guide to Methods and Applications, Innis et al., eds, 1990; Sambrook and Russell, MOLECULAR CLONING, A LABORATORY MANUAL (3rd ed. 2001); and CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (Ausubel et al., eds., John Wiley & Sons, Inc. 1994-1997, 2001 version).
  • Long PCR refers to the amplification of a DNA fragment of 5 kb or longer in length. Long PCR is typically performed using specially-adapted polymerases or polymerase mixtures (see, e.g., U.S. Pat. Nos. 5,436,149 and 5,512,462) that are distinct from the polymerases conventionally used to amplify shorter products.
  • a “primer” refers to a polynucleotide sequence that hybridizes to a sequence on a target nucleic acid and serves as a point of initiation of nucleic acid synthesis.
  • Primers can be of a variety of lengths and are often less than 50 nucleotides in length, for example 12-25 nucleotides, in length.
  • the length and sequences of primers for use in PCR can be designed based on principles known to those of skill in the art, see, e.g., Innis et al., supra.
  • a “capture oligonucleotide” refers to an oligonucleotide attached to a discrete location, which is used for hybridizing to polynucleotides present in solution and causing them to remain in association with the discrete location.
  • oligonucleotide refers to natural or synthetic chemical substances that are capable of hybridizing with polynucleotides, or otherwise substituting for natural polynucleotides in enzymatic reactions. Oligonucleotides include polymers containing non-natural monomers such as modified bases and peptide nucleic acid (PNA) monomers.
  • PNA peptide nucleic acid
  • a “probe” refers to a polynucleotide sequence capable of hybridization to a polynucleotide sequence of interest and allows for the detecting of the polynucleotide sequence of choice.
  • “probes” can comprise polynucleotides linked to fluorescent or quenching reagent, thereby allowing for the detection of these reagents.
  • sequence refers to a sequence of nucleotides that are contiguous within a second sequence but does not include all of the nucleotides of the second sequence.
  • target refers to a single or double stranded polynucleotide sequence sought to be amplified in an amplification reaction. Two target sequences are different if they comprise non-identical polynucleotide sequences.
  • a “temperature profile” refers to the temperature and lengths of time of the denaturation, annealing and/or extension steps of a PCR reaction.
  • a temperature profile for a PCR reaction typically consists of 10 to 60 repetitions of similar or identical shorter temperature profiles; each of these shorter profiles typically define a two step or three-step PCR reaction. Selection of a “temperature profile” is based on various considerations known to those of skill in the art, see, e.g., Innis et al., supra.
  • the extension time required to obtain an amplification product of 5 kb or greater in length is reduced compared to conventional polymerase mixtures.
  • Amplification or PCR “sensitivity” refers to the ability to amplify a target nucleic acid that is present in low copy number. “Low copy number” refers to 10 5 , often 10 4 , 10 3 , 10 2 , or fewer, copies of the target sequence in the nucleic acid sample to be amplified.
  • a “template” refers to a double stranded polynucleotide sequence that comprises the polynucleotide to be amplified, flanked by primer hybridization sites.
  • a “target template” comprises the target polynucleotide sequence flanked by hybridization sites for a 5′ primer and a 3′ primer.
  • query position refers to the target polymorphic nucleotide or other polymorphism targeted by an assay of the invention.
  • Multiplex amplification refers to amplification of multiple polynucleotide fragments in the same reaction (see, e.g., PCR PRIMER, A LABORATORY MANUAL (Dieffenbach, ed. 1995) Cold Spring Harbor Press, pages 157-171.
  • polymorphism is an allelic variant. Polymorphisms can include single nucleotide polymorphisms as well as simple sequence length polymorphisms. A polymorphism can be due to one or more nucleotide substitutions at one allele in comparison to another allele or can be due to an insertion or deletion.
  • a “solid support” refers to any material to which an oligonucleotide can be attached or any material that can be modified so that an oligonucleotide can be attached to it.
  • Illustrative solid surfaces or solid supports include, e.g., nitrocellulose, nylon, glass, quartz, polystyrene, diazotized membranes (paper or nylon), silicones, polyformaldehyde, cellulose, and cellulose acetate.
  • plastics such as polyethylene, polypropylene, polystyrene, and the like can be used.
  • Other materials which may be employed include paper, ceramics, metals, metalloids, semiconductive materials, cermets or the like.
  • substances that form gels can be used.
  • Such materials include, e.g., proteins (e.g., gelatins), lipopolysaccharides, silicates, agarose and polyacrylamides.
  • proteins e.g., gelatins
  • lipopolysaccharides e.g., silicates
  • agarose e.g., glycerol, glycerol, glycerol, glycerol, glycerol, g., g., g., g., celluloses), lipopolysaccharides, silicates, agarose and polyacrylamides.
  • polyacrylamides e.g., polyacrylamides
  • the invention provides an error-correction polymorphism assay PACE, for Polymorphism Assay by Correction of Errors, which is capable of robust operation from small amounts of genomic DNA and several schemes for parallelizing this assay for low-cost, high throughput operation.
  • the assay is typically performed using an improved error-correcting polymerase that comprises a thermostable sequence-nonspecific double-stranded DNA-binding domain, e.g., Sso7d, attached to the polymerase, or a catalytic domain of the polymerase, which increases the processivity of the polymerase.
  • one labeled oligonucleotide may be complementary to the undeleted DNA, with its 3′ end corresponding to the first nucleotide that is different in the deletion allele; the other labeled oligonucleotide may be identical to the first, except that the 3′ end is complementary to the sequence found in the deletion allele. Similar logic can be used to design PACE primers to detect insertions, inversions, and multi-base sequence changes.
  • Polymerases with 3′ nuclease activity are suitable for the assays.
  • Such polymerases include Pyrococcus polymerases such as Pfu, Pho, Pab, Pko, Pgl etc. and Thermococcus polymerases such as Tli (Vent), which are sufficiently thermostable to be suitable for PCR.
  • Other polymerases that are not thermostable may also be used.
  • E. coli PolA has 3′ to 5′ exonuclease activitiy and could be used in an embodiment where the error correcting step is not performed at high termperatures.
  • Engineered polymerases with 3′ nuclease activity that have at least 60% amino acid similarity to any natural error-correcting polymerase may also be used. Typically, these polymerases are modified by fusion with thermostable sequence-nonspecific double-stranded DNA-binding proteins such as Sso7d for use in the assay.
  • the polymerase is a fusion of Sso7d to the C-terminus of Pfu polymerase, an enzyme referred to as Pfu-Sso7d or “PfS”.
  • PfS performs an error-correcting assay including amplification directly from genomic DNA of low copy number templates in circumstances where Pfu does not work.
  • Example 2 shows that amplification with PfS distinguishes two different templates with a single nucleotide difference between them, as well as a 50:50 mixture of the two.
  • This invention uses the error-correcting SNP assay for parallel methods of scoring single nucleotide polymorphisms, by modifying it so that it can be highly multiplexed. Rather than multiplexing by increasing the number of distinguishable fluorescent colors, the multiplex reactions of the current invention use only a small number of colors in a large number of discrete locations.
  • Assay 1 Amplification in the Presence of a Labeled Array.
  • An important concept in this assay is to employ oligonucleotides attached to discrete locations, where the attachment method permits a free 3′ end to serve as a potential substrate for the 3′ nuclease activity of a polymerase.
  • the 3′ nucleotide is labeled, and the assay as performed surveys the discrete locations to determine whether a significant fraction, i.e., more than in a negative control, of the 3′ nucleotides attached to a particular location have been clipped off.
  • a PCR is performed in solution, using two unlabeled oligonucleotide primers, where the query position occurs within the amplicon but is not found in either primer;
  • a labeled (probe) oligonucleotide containing the labeled query position as its 3′ nucleotide is attached to a discrete surface location by a linkage that does not include the 3′ nucleotide (i.e., the 3′ nucleotide is free to participate in enzymatic reactions).
  • the labeled oligonucleotide can be attached by a functional group on its 5′ end.
  • the probe is long enough to hybridize to an amplicon in solution that comprises the query position.
  • the probe is typically at least 12-14 nucleotides in length, but can be longer, e.g., 25-30 nucleotides in length depending on the T M .
  • new technologies e.g., minor groove binders (MGB) from Synthetic Genetics can increase the affinity so that the probe can also be about 10 bases in length.
  • the discrete surface location may be on any solid support.
  • the discrete location is a spot on a microarray, such as is commonly constructed on a glass slide with a flat or porous surface, or is a fluorescently-labeled bead, such as the polystyrene beads commercially available from Luminex (Austin Tex.) or which have been developed by the Quantum Dot Corporation of Hayward Calif., or such as described by M. Han et al. (“Quantum dot tagged microbeads for multiplex coding of biomolecules.” Nature Biotechnology, 19:7, 631-635, 2001).
  • the label on the 3′ query nucleotide of the probe oligonucleotide is a quencher, and the corresponding fluor is attached to the probe oligo somewhere close to, e.g., within about 25 or 30 bases, preferably about 10 bases, but separate from the 3′ nucleotide.
  • the quencher can be a non-fluorescent molecule such as DABCYL. The purpose of this is to make the unreacted probe oligonucleotide have a low fluorescence due to the quencher, so that even small increases in fluorescence, resulting from a small amount of clipping of the 3′ nucleotide, will be detectable.
  • the unlabeled amplification primers can be designed so as to amplify a significant amount of sequence not present in either primer—for instance, at least 3 and as many as 15 or more bases, e.g., 50, 100, 500, 1000, 5000 or more bases.
  • At least part of the probe i.e., a subsequence of the probe, is complementary to the sequence not present in either primer.
  • the subsequence of the probe not complementary to either primer is increased until the probe oligonucleotides are functionally specific for a true template-derived amplicon, and not affected by a primer-dimer or similar artifact.
  • Taqman-type cleavage of the probe is not an issue if a polymerase with no 5′-3′ exonuclease activity is used (e.g., Pyrococcus -type polymerases).
  • the probe sequence is designed to discriminate between other amplicons that may be present in the reaction, i.e., it will hybridize to one amplicon and not to the others.
  • Exemplary hybridization conditions are typically compatible with amplification reactions, e.g., hybridization can be performed at 50 mM KCl, 10 mM Tris pH8.5, 1.5 mM Mg ++ at a temperature that is usually between 60° C. and 72° C.
  • At least two probe oligonucleotides are employed. They can be in a single discrete location and distinguished from each other by means of color, or they can be in separate discrete locations.
  • the assays can be highly multiplexed, so that at least dozens, and perhaps many thousands of different assays can be performed together in the same solution.
  • the probe oligonucleotides are designed to have about the same T M using algorithms well known to those of skill in the art.
  • the probes typically have a T M within 10° C. of one another, more often between 5° C. or 2° C. of one another.
  • the assay differs from the Genome Therapeutics protocol by at least elements 1, 2, 3, and 4.
  • the assay can be further improved by addition of elements 5, 6, 7, 8, and 9 singly or in combinations.
  • amplifications are performed, typically directly from genomic DNA, and the assay is read out, i.e., the results are determined, by hybridization to probes fixed to a discrete location on a solid support, e.g., a microarray.
  • this assay is performed by PCR amplification, where one of the primers has the polymorphic sites, e.g., an SNP site, at its 3′ end, and that base contains a fluorescent label.
  • Read-out is accomplished by hybridizing the amplified DNA to an unlabelled microarray and determining the amount of fluorescent signal at particular known locations relative to controls. In general, such an assay would be multiplexed.
  • Additional embodiments of this assay include, but are not limited to, the following:
  • each polymorphism e.g., an SNP
  • more than one 3′ base-labeled oligonucleotide is used, with each different base having a different color label. Only those bases corresponding to polymorphic alleles present in the sample will be extended at any significant rate, and thus only colors corresponding to those bases will be significantly incorporated into the amplified DNA. Therefore, after hybridization, the colors present at an array site expected to hybridize to a particular product correspond to the polymorphism alleles present in the original sample. In this case, each allele and heterozygotes are distinguishable by the ratios of the amount of each color present, and are all clearly distinguishable from reaction failures, which have no or very little color present.
  • the amplicon may contain some sequence, preferably at least 10 bases, that is not contained in either of the two PCR primers, and hybridization to the array may depend on the presence of this sequence. Amplicons may be large, with reliable amplification of at least 5 kb being known in the art. Therefore it should always be possible to find a set of sufficiently non-cross-hybridizing sequences sufficiently close to a polymorphic site, e.g., an SNP site, so that specific arrays may be constructed.
  • a polymorphic site e.g., an SNP site
  • a set of pre-determined hybridization sites may be incorporated into the non-labeled primers for each amplicon, and these predetermined sites may be used as a basis for differential hybridization to an array. This method allows the use of standard arrays for many different polymorphism-scoring assays, through the incorporation of the same set of pre-determined hybridization sites into the unlabeled oligonucleotides of each different assay.
  • method A An advantage of method A is that it assures that only amplification products corresponding to the correct locus will be contribute to the hybridization signal.
  • method B can be sufficiently specific, and can be justified by the cost advantage of using standard arrays. Methods A and B may also be used in combination in a single experiment.
  • Arrays may be labeled with a fluor, and the read-out may be on the basis of FRET between the array and the amplicon.
  • Oligonucleotides may be double-labeled with two fluors or a fluor and a quencher, and readout may depend on changes in fluorescence due to removal of one moiety.
  • This assay is similar to Assay 2, with a different readout mechanism. Amplifications are performed, preferably directly from genomic DNA, and the assay is read out by electrophoretic analysis with fluorescent detection. In general, this assay is performed by PCR amplification, where one of the primers has the polymorphic, e.g., a SNP site, at its 3′ end, and that base contains a fluorescent label. Electrophoretic analysis is accomplished by capillary or gel electrophoresis instruments well known in the art, intended for fluorescent automated DNA sequencing or other types of fluorescent DNA fragment analysis. In general, such an assay would be multiplexed. Additional refinements are also possible and include, but are not limited to, the following:
  • Multiple polymorphic sites such as SNP sites, may be assayed in a single electrophoretic run by the simple expedient of adjusting the amplicon size so that each polymorphic site corresponds to a distinguishable amplicon size.
  • This adjustment can be made by choosing the sequence of the unlabeled primer to correspond to sequences at various distances from the SNP site. In some instances, a particular primer sequence may be disfavored because of its potential for illegitimate hybridization; in this case, a different length can be chosen, or the strand of the labeled primer may be switched.
  • a typical electrophoretic instrument such as the BaseStation (MJ Research, Waltham Mass.) can easily resolve fragments at four-base intervals to lengths greater than 1100 bases in 96 sample lanes simultaneously. If each lane contains alleles starting at 80 bases (so as to be separated from free dye breakdown products and primer-dimer artifacts) and continuing to 1100 bases, over 250,000 determinations cam be made in a four-hour run on a single instrument
  • Oligonucleotides used in the invention typically containing base-linked fluors and quenchers are well-known in the art. They can be obtained, for example, from Life Technologies (Gaithersburg, Md.), Sigma-Genosys (The Woodlands, Tex.), Genset Corp. (La Jolla, Calif.), or Synthetic Genetics (San Diego, Calif.).
  • the primers for the amplification reactions are designed according to known algorithms. Typically, commercially available or custom software will use algorithms to design primers such that that annealing temperatures are close to melting temperature. Typically, the primers are at least 12 bases, more often 15, 18, or 20 bases in length. Primers are typically designed so that all primers participating in a particular reaction have melting temperatures that are within 5° C., and most preferably within 2° C. of each other. Primers are further designed to avoid priming on themselves or each other. Primer concentration should be sufficient to bind to the amount of target sequences that are amplified so as to provide an accurate assessment of the quantity of amplified sequence. Those of skill in the art will recognize that the amount of concentration of primer will vary according to the binding affinity of the primers as well as the quantity of sequence to be bound. Typical primer concentrations will range from 0.01 ⁇ M to 0.5 ⁇ M.
  • the polymerase reactions are incubated under conditions in which the primers hybridize to the target sequences and are extended by a polymerase.
  • reaction conditions may vary, depending on the target sequence and the composition of the primer.
  • the amplification reaction cycle conditions are selected so that the primers hybridize specifically to the target sequence and are extended. Exemplary PCR conditions for particular primer sets are provided in the examples.
  • base-linked fluors are incorporated into the oligonucleotdies by post-synthesis modification of oligonucleotides that were synthesized with reactive groups linked to bases.
  • fluorophores include from commercial sources such as Molecular Probes, Eugene, Oreg. and other fluorophores known to those of skill in the art.
  • Molecular Probes include Molecular Probes, Eugene, Oreg. and other fluorophores known to those of skill in the art.
  • each probe will fluoresce at a different wavelength and can be individually detected without interference from the other probes.
  • Fluorescence-based assays can also rely for signal generation on fluorescence resonance energy transfer, or “FRET”, according to which a change in fluorescence is caused by a change in the distance separating a first fluorophore from an interacting resonance energy acceptor, either another fluorophore or a quencher.
  • FRET fluorescence resonance energy transfer
  • Combinations of a fluorophore and an interacting molecule or moiety, including quenching molecules or moieties, are known as “FRET pairs.”
  • the mechanism of FRET-pair interaction requires that the absorption spectrum of one member of the pair overlaps the emission spectrum of the other member, the first fluorophore. If the interacting molecule or moiety is a quencher, its absorption spectrum must overlap the emission spectrum of the fluorophore.
  • a variety of labeled nucleic acid hybridization probes and detection assays that utilize FRET and FRET pairs are known.
  • One such scheme is described by Cardullo et al. Proc. Natl. Acad. Sci. USA 85: 8790-8794 (1988) and in Heller et al. EP 0070685. It uses a probe comprising a pair of oligodeoxynucleotides complementary to contiguous regions of a target DNA strand.
  • One probe molecule contains a fluorescent label, a fluorophore, on its 5′ end, and the other probe molecule contains a different fluorescent label, also a fluorophore, on its 3′ end.
  • FRET fluorescence resonance energy transfer from one label to the other occurs.
  • FRET produces a measurable change in spectral response from the labels, signaling the presence of targets.
  • One label could be a “quencher,” which in this application is meant an interactive moiety (or molecule) that releases the accepted energy as heat.
  • any solid support including, but not limited to membrane filters, slides, microparticles and the like, may be used in the methods of the invention.
  • microarrays are used. Labeled arrays, e.g., those used in assay 1, are constructed by attachment of separately-synthesized oligonucleotides using any of several attachment chemistries, below. Unlabeled oligonucleotides, e.g., those prepared for Assay 2, may be attached by such methods, and additionally may be synthesized directly in situ by various techniques. Such arrays are made, e.g., by Affymetrix (Santa Clara Calif.) and Rosetta Inpharmics (Kirkland Wash.).
  • probe oligonucleotides used e.g., in Assay 1 must have free 3′ ends, they cannot be synthesized on the surface where they will be used by conventional phosphoramidite chemistry, which results in the 3′ end being attached to the substrate. Instead, they are synthesized separately, with a functional group, such as an amino, acrylic (Mosaic Technologies, Boston Mass.), or thiol group, on the 5′ end. Appropriate surfaces with functional groups are readily available. For example, glass slides are conventionally available with aminosilane or poly-L-lysine coatings providing amino groups.
  • Glass slides may be modified via silane chemistry to have a reactive vinyl group, and may be coupled to an oligonucleotide containing an acrylic group via radical vinyl polymerization, for instance in the presence of acrylamide monomers.
  • Polystyrene beads are conventionally available with carboxyl groups on their surfaces. Other types of surface groups can be obtained through conventional chemical manipulations. These functional groups can be used to link the oligonucleotides to the surface through conventional chemistries.
  • the oligonucleotides are attached to the discrete surface locations.
  • the reaction described herein can be highly multiplexed. Not to be bound by theory, the reactions can be highly multiplexed for the following reasons.
  • unwanted, non-specific reaction products can be kept to a minimum by primer design, use of minimal primer concentration, and close control over reaction conditions.
  • primers are designed to have about the same T M , usually within 10° C., often 5° C., or 2° C.
  • the primers are also designed to avoid producing a PCR product by mispairing.
  • the reaction is controlled to keep the annealing and extensions temperatures such that the primers do not prime at incorrect sites at a detectable level.
  • Polymerases are well-known to those skilled in the art. These include both DNA-dependent polymerases and RNA-dependent polymerases such as reverse transcriptase. At least five families of DNA-dependent DNA polymerases are known, although most fall into families A, B and C. There is little or no structural or sequence similarity among the various families. Most family A polymerases are single chain proteins that can contain multiple enzymatic functions including polymerase, 3′ to 5′ exonuclease activity and 5′ to 3′ exonuclease activity. Family B polymerases typically have a single catalytic domain with polymerase and 3′ to 5′ exonuclease activity, as well as accessory factors.
  • Family C polymerases are typically multi-subunit proteins with polymerizing and 3′ to 5′ exonuclease activity.
  • DNA polymerases I family A
  • II family B
  • III family C
  • family B family B polymerases
  • DNA polymerases ⁇ , ⁇ , and ⁇ are implicated in nuclear replication
  • a family A polymerase, polymerase ⁇ is used for mitochondrial DNA replication.
  • Other types of DNA polymerases include phage polymerases.
  • Polymerases with 3′ to 5′ exonuclease activity are used in the invention. These include family B polymerases such as Pyrococcus polymerases such as Pfu, Pho, Pab, Pko, Pgl etc. and Thermococcus polymerases such as Tli (Vent), which are sufficiently thermostable to be suitable for PCR. Family A polymerases that have error-correcting activity may also be used, e.g., Tth. Further, in some embodiments, non-thermostable polymerases may be used. For example, E. coli PolI has 3′ to 5′ exonuclease activitiy and could be used in an embodiment where the error correcting step is not performed at high temperatures.
  • polymerases having enhanced processivity include those described in WO01/92501. These improved polymerases exhibit enhanced processivity due to the presence of a sequence-non-specific double-stranded DNA binding domain that is joined to the polymerase or the enzymatic domain of the polymerase). Often the binding domain is from a thermostable organism and provides enhanced activity at higher temperatures, e.g., temperatures above 45° C. For example, Sso7d and Sac7d are small (about 7,000 kd MW), basic chromosomal proteins from the hyperthermophilic archaeabacteria Sulfolobus solfataricus and S.
  • improved polymerases are used. These polymerases can be used to obtain long, i.e., 5 kb, often 10 kb, or greater in length, PCR products. “Long PCR” using these improved polymerases can be performed using extension times that are reduced compared to prior art “long PCR” polymerase and/or polymerase mixtures. Extension times of less than 30 seconds per kb, often 15 seconds per kb, can be used to amplify long products in PCR reactions using the improved polymerases. Furthermore, these modified polymerases also exhibit increased sensitivity.
  • Prior-art non-error-correcting polymerases such as Taq polymerase are capable of amplifying DNA from very small input copy concentrations, such as, in the extreme, 10 copies per ml. However, because of the low fidelity of such polymerases, products cloned from such amplifications are likely to contain introduced mutations.
  • Prior-art error-correcting polymerases such as Pfu copy DNA with higher fidelity than Taq, but are not capable of amplifying DNA from small input copy concentrations.
  • the hybrid error-correcting polymerases of the invention exhibit much higher processivity while retaining error-correcting activity and thereby provide both sensitivity and fidelity in amplification reactions.
  • Typical reactions may be set up as follows:
  • Assay 1 Genomic DNA from an individual to be tested is mixed with a PCR mixture containing an appropriate polymerase and one unlabelled primer pair for each locus to be tested. The reaction mixture is placed into a vessel and put into contact with surfaces to which probe oligonucleotides are attached.
  • the combination of a vessel and surfaces for probe attachment can be satisfied in several ways: for instance, a standard plastic thermal cycling reaction vessel containing color-coded polystyrene beads to which probes are attached; or a glass slide with probes attached in discrete spots, and an appropriate chamber or cover for containing the reaction volume. The vessel is then thermally cycled to allow the PCR and assay to proceed.
  • Genomic DNA from an individual to be tested is mixed with a PCR mixture containing an appropriate polymerase and one primer pair for each locus to be tested, where a primer pair consists of one labeled and one unlabeled primer. After amplification, all separate amplification tubes are combined, and the products are denatured and analyzed by the method of choice.
  • At least some amplification may take place before the solution containing DNA to be tested is exposed to the surface with attached probe oligonucleotide.
  • An amplification other than PCR such as transcription-mediated amplification (TMA), strand displacement amplifcation (SDA), nucleic acid sequence-based amplification (NASBA), LCR, oligonucleotide ligation assay (OLA), etc., may be employed. In this case, concurrent amplification may not be used.
  • Fluorescence may be quantified in the discrete locations by any of several methods. Numerous commercially-available instruments, such as those manufactured by Axon Instruments (Foster City, Calif.) and Applied Precision (Issaquah, Wash.) can quantify fluorescence from spots on the surface of a flat substrate. Fluorescent-coded beads can be read using flow-cytometry-type instrumentation, such as that manufactured by Luminex (Austin, Tex.). Other optical properties besides color of fluorescent emissions can be used to distinguish reaction products—for instance, time-resolved fluorescence.
  • an increase in fluorescence, relative to a control, from a discrete location in a particular color indicates that the 3′ nucleotide of the probe corresponding to that location and color does not match at least some of the amplicons present in the solution.
  • the expected pattern is a large increase in fluorescence for each probe with a 3′ mismatch.
  • Modified Error-Correcting Enzymes are Superior to Unmodified Error-Correcting Enzymes in Amplifying DNA from Low Copy Number Templates.
  • PCR was performed in the presence of the double-stranded-DNA-specific fluorescent dye SYBR Green I (Molecular Probes, Eugene Oreg.) in a DNA Engine Opticon continuous fluorescence detection thermal cycling system (MJ Research, Waltham Mass.).
  • SYBR Green I Molecular Probes, Eugene Oreg.
  • SYBR Green I Molecular Probes, Eugene Oreg.
  • a 57 bp portion of the human cytochrome P450 gene CYP2D6 was amplified using primers F1 (forward) and R1 (reverse) from a template containing a perfect match to both primers.
  • the number of thermal cycles required for the fluorescence to reach a threshold value was recorded.
  • the C t value represents the number of cycles required to generate a detectable amount of DNA.
  • a “detectable” amount of DNA is at least 2 standard deviations, and usually 5 or more standard deviations above the background noise level. In the conditions employed in this example, a detectable amount corresponds to approximately 1 ng of DNA.
  • An efficient polymerase may be able to produce a detectable amount of DNA in a smaller number of cycles by more closely approaching the theoretical maximum amplification efficiency of PCR. Accordingly, a lower C t value reflects a greater amplification efficiency for the enzyme.
  • the enzymes tested were Pfu (Stratagene, La Jolla Calif.) and PfS, a fusion of Sso7d to the carboxy terminus of Pfu, as described in the co-pending U.S. application Ser. No. 09/870,353. Each enzyme was tested over a range of concentrations from 40 units/ml to 5 units/ml. PfS was found to require between 1 ⁇ 4 and 1/10 as many units as Pfu for efficient amplification. Each enzyme was used in its optimal buffer.
  • Primer F1 AGG CGC TTC TCC GTG (SEQ ID NO:1)
  • Primer R1 CTC CAG CGA CTT CTT GC (SEQ ID NO:2) Reaction Conditions
  • PfS amplified the template with high efficiency at enzyme concentrations from 10-40 U/ml at all input DNA copy numbers, down to 10 copies.
  • PfS showed slightly less efficient amplification at 5 U/ml.
  • Pfu only amplified the template efficiently at 40 U/ml, and even then, only down to an input copy number of 1000 copies.
  • amplification was inefficient, and in many cases did not result in a detectable product generated within the 46 cycles of the experiment.
  • PCR was performed using a 3′ base-labeled primer in conditions where it had either a perfect match with the template, or a 3′ single-base mismatch with the template.
  • Primer F2 was the base-labeled primer, with the same sequence as primer F1 except the 3′ G (query position) is replaced with a C with a carboxyfluorescein (FAM) dye attached at the 5 position through a linker. 10 6 copies of plasmid clones with either a G or a C in the polymorphic position were used as templates.
  • the reverse primer, R2 was designed to produce a 475-base amplicon. Enzymes used were Taq Gold (ABI, Foster City Calif.), PfS, and Pfu. Six PCRs were performed, with all combinations of the three enzymes and two templates.
  • FIG. 1 shows an aliquot of each reaction run on an agarose gel and stained with ethidium bromide. Products were produced in all reactions, though there was a lower yield for the mismatch condition with Taq and Pfu. The overall yield was highest with PfS.
  • PCR was performed using a 3′ base-labeled primer in conditions where it had either a perfect match with the template, or a 3′ single-base mismatch with the template.
  • Two labeled primers were used: F2 and F3 were base-labeled, with the same sequence as primer F1 except the 3′ G (query position) is replaced with a C with a carboxyfluorescein (FAM) dye attached at the 5 position through a linker o or a T labeled with Bodipy R6G (BR6G) (Molecular Probes, Eugene Oreg.) linked to the T methyl group via a 6-carbon linker. 10 6 copies of plasmid clones with either a G or a C in the polymorphic position were used as templates.
  • FAM carboxyfluorescein
  • the reverse primer, R2 was designed to produce a 475-base amplicon. Enzymes used were Taq Gold (ABI, Foster City Calif.), PfS, and Pfu. Twenty seven PCRs were performed, with all combinations of the three enzymes, two primers singly and in combination, and two templates singly and in combination.
  • Primer F3 was poorly labeled (only about 7% of molecules were dye-labeled) so it was used at a higher concentration than primer F2 to compensate for that difference.
  • Primer F2 AGG CGC TTC TCC GTC (FAM) (SEQ ID NO:3)
  • Primer F3 AGG CGC TTC TCC GTT (R6G) (SEQ ID NO:5)
  • Primer R2 ATG TCC TTT CCC AAA CCC AT (SEQ ID NO:3)
  • PCR products were analyzed electrophoretically on a BaseStation fluorescent electrophoretic analyzer (MJ Research, Waltham Mass.). Fluorescence intensity traces for each lane were baseline subtracted, but no attempt was made to perform a color separation deconvolution. Table 2 summarizes the results. The numbers presented in Table 2 are the heights of peaks corresponding to a 475-base fragment. If no peak was detectable, no number is given. Channel 1 is about twice as sensitive to FAM as BR6G, while channel 2 is about twice as sensitive to BR6G as FAM. So a pure peak of one dye will result in a peak in its corresponding channel and a peak of half that height in the other channel.
  • FIG. 2 all three panels are electropherograms of reactions from Example 3 employing mixed C and T labeled primers.
  • Channel 1 signal is in black and channel 2 signal is in grey.
  • the top panel was from Lane 12, the reaction with G template, and channel 1 signal is double that from channel 2, indicating a pure C peak.
  • the center panel was from Lane 15, the reaction with A template, and channel 2 signal is double that from channel 1, indicating a pure T peak.
  • the bottom panel was from Lane 18, the reaction with mixed Aand G template, and channel 1 and channel 2 signals are approximately equal, indicating a both a C and a T peak.
  • the channel 1 and 2 signals are not coincident, corresponding to a small mobility difference between the two dyes, further reinforcing the conclusion that both labeled peaks are present.

Abstract

This invention provides a method of detecting polymorphisms, e.g., single nucleotide polymorphisms (SNPs), by amplification and error correction. The invention encompasses methods of performing amplification and error correction using an improved generation of nucleic acid polymerases, and methods of multiplexing the assay. The improvement to the polymerases is the joining of a sequence-non-specific nucleic-acid-binding domain to the enzyme in a manner that enhances the ability of the enzyme to bind and catalytically modify the nucleic acid.

Description

    CROSS-REFERENCES TO RELATED APPLICATIONS
  • This application is a continuation of co-pending application Ser. No. 10/306,828 filed Nov. 27, 2002, which claims the benefit of U.S. provisional application No. 60/334,032, filed Nov. 28, 2001, which are incorporated by reference herein.
  • FIELD OF THE INVENTION
  • This invention provides a method of detecting polymorphisms, e.g., single nucleotide polymorphisms (SNPs) by amplification and error correction. The invention encompasses methods of performing amplification and error correction using an improved generation of nucleic acid polymerases, and methods of multiplexing the assay. The improvement to the polymerases is the joining of a sequence-non-specific nucleic-acid-binding domain to the enzyme in a manner that enhances the ability of the enzyme to bind and catalyticly modify the nucleic acid.
  • BACKGROUND OF THE INVENTION
  • The smallest possible difference between two DNA sequences is a change of a single base, a Single Nucleotide Polymorphism or SNP. Such differences are common in the human population, occurring roughly one every 1000 bases between any two unrelated individuals. Some SNPs have medically important consequences, while others are silent but may be useful as markers to study genetic transmission of traits.
  • A number of methods have been developed to score SNPs, including allele-specific hybridization, electrophoretic DNA sequencing, single-nucleotide extension using labeled chain terminators, the “Invader” assay (Third Wave Technologies, Madison Wis.), mass spectrometry, the 5′ nuclease assay (Taqman; see below), etc. All of these methods entail assays that are either difficult or expensive to develop, or difficult or expensive to perform.
  • It will be appreciated that while SNPs are common, it is at times advantageous to score other polymorphisms such as insertions, deletions, rearrangements or sequence alterations involving more than one base. SNP scoring has been emphasized in the literature because it is the most difficult case, but most methods capable of scoring SNPs are also capable of scoring additional types of polymorphisms.
  • One of the known assays for detecting single-base differences in DNA samples uses an exonuclease specific for mismatched bases (see, e.g., U.S. Pat. No. 5,391,480). In general, such an assay involves labeling the 3′ nucleotide in a primer with a fluorescent marker. The labeled oligonucleotide is hybridized to an unknown DNA sample. If the 3′ nucleotide (the query position) of the oligonucleotide is complementary to the corresponding nucleotide in the hybridized DNA, it will be insensitive to nuclease; if there is a mismatch it will be sensitive to nuclease and will be cleaved. For example, in a PCR reaction, the query position corresponds to the 3′ end of one of the two primers. This primer is synthesized in two versions (1 and 2), one complementary to each of the two expected versions of a SNP ( SNP versions 1 and 2, respectively). The 3′ nucleotides of primers 1 and 2 are labeled with distinguishable fluors. The polymerase used for the PCR is one capable of excising mismatched 3′ nucleotides (an “error-correcting” or “3′ exonuclease-activity-containing” polymerase). If the input template contains SNP version 1, then primer 2 will at some frequency anneal to an amplicon containing SNP version 1 and the 3′ nucleotide will be clipped off by the error-correcting activity of the polymerase. Clipped-off fluorescent nucleotides are detected by a decrease in fluorescence polarization (FP). At the same time, primer 1, which is fully complementary to SNP version 1, will at some frequency anneal to an amplicon containing SNP version 1 and be extended to full amplicon length. The extended primer then becomes insensitive to further attack by nuclease. Thus, if SNP version 1 is present, there will be a decrease in FP for the fluor linked to primer 2; if SNP version 2 is present, there will be a decrease in FP for the fluor linked to primer 1; if both SNP versions are present (as in a heterozygote), then there will be a decrease in FP for both fluors, but to a smaller extent for each.
  • Commercially-available polymerases such as Pfu are capable of extending a labeled nucleotide if it is correctly matched and clipping it if it is mismatched. The procedure is also distinct from the “Taqman” assay (see, e.g., U.S. Pat. Nos. 5,210,015 and 5,487,972), which uses the 5′-3′ nuclease activity of some thermostable polymerases.
  • There are a number of problems and deficiencies with this method, however. First, known error-correcting polymerases, such as the Pyrococcus genus family B polymerases, are ill-suited to amplification of sequences directly from genomic DNA. The processivity of the polymerases is too low to reliably complete a full-length copy of an amplicon in a single round. Thus, completion of a full length copy must rely on hybridization of the partial copies to a suitable template in the reaction mix, and therefore only occurs if the template concentration is relatively high. This creates a problem, because it is preferable to use low amounts of genomic DNA in a PCR reaction in order to allow use of DNA that is not highly purified; and to reduce the amount of non-specific DNA, which can lead to side reactions, present in the reaction. The prior art protocol is therefore conventionally performed by 1) pre-amplifying a region containing the SNP site using unlabeled primers and Taq or other polymerase capable of amplifying single copies, 2) purifying the amplified DNA, 3) re-amplifying with labeled primers and an error-correcting polymerase, and 4) detecting whether error correction has occurred.
  • Second, the methods used for scoring whether error correction has occurred (and therefore what versions of an SNP are present in the original sample) are inadequate for low cost and high throughput. Given the cost of reagents and disposables, and the amortized cost of equipment and space, it is exceedingly difficult to run a PCR for less than 10-20 US cents. Yet, for many applications, SNP scoring is not economical unless it can be done for 1 US cent per locus. Therefore, it is necessary to score at least ten and perhaps many more SNPs per PCR. Assays based on scoring with FP can score no more than 1 or 2 SNPs per PCR.
  • The current invention meets the need for an economical SNP assay that can be performed using small amounts of genomic DNA. Here, we describe an error-correction SNP assay capable of robust operation from small amounts of genomic DNA and several methods for parallelizing this assay for low-cost, high throughput operation.
  • The processivity of a polymerase, i.e., the amount of product generated by the enzyme per binding event, can be enhanced by increasing the stability of the modifying enzyme/nucleic acid complex. Co-pending U.S. application Ser. No. 09/870,353 and WO01/92501 disclose modified polymerases that have increased processivity that is achieved by joining a sequence-non-specific double-stranded nucleic acid binding domain to the enzyme, or its catalytic domain. Among the modified polymerases disclosed are error-correcting Family B polymerases, which typically are used in the current invention.
  • BRIEF SUMMARY OF THE INVENTION
  • The current invention provides methods of identifying a polymorphism using an error-correcting assay. A first method comprises: (a) contacting a target nucleic acid comprising a query sequence with a probe oligonucleotide under conditions in which the probe specifically hybridizes to the target nucleic acid, wherein the 3′ nucleotide of the probe is a labeled query nucleotide and the probe oligonucleotide is attached to a discrete surface location, e.g., in a microarray, by a linkage that does not include the 3′ nucleotide; (b) providing an error-correcting polymerase; (c) incubating the assay under conditions in which the probe is extended by the polymerase, wherein the labeled query nucleotide is cleaved from the probe when mismatched with the query sequence; and (d) detecting the amount of probe in the discrete location that has been cleaved.
  • A second method comprises: (a) contacting a target nucleic acid comprising a query sequence with a probe oligonucleotide under conditions in which the probe specifically hybridizes to the target nucleic acid, wherein the 3′ nucleotide of the probe is a labeled query nucleotide; (b) providing an error-correcting polymerase; (c) incubating the assay under conditions in which the probe is extended by the polymerase, wherein the labeled query nucleotide is cleaved from the probe when mismatched with the query sequence; (d) providing a capture oligonucleotide attached to a discrete location and complementary to the product of the extended probe; (e) allowing the product of the extended probe the opportunity to hybridize with the capture oligonucleotide; and (f) determining the amount of label associated with the discrete location.
  • A third method comprises: (a) contacting a target nucleic acid comprising at least two query sequences with at least two probe oligonucleotides under conditions in which the probes specifically hybridize to the target nucleic acid, wherein the 3′ nucleotides of the probes are labeled query nucleotides; (b) providing an error-correcting polymerase; (c) incubating the assay under conditions in which the probes are extended by the polymerase, wherein the labeled query nucleotides are cleaved from the probe when mismatched with the query sequences; (d) separating the products of the extended probes electrophoretically; and (e) determining the amount of label associated with the products of each extended probe.
  • A fourth method comprises: (a) contacting a target nucleic acid comprising a query sequence with a probe oligonucleotide under conditions in which the probe specifically hybridizes to the target nucleic acid, wherein the 3′ nucleotide of the probe is a labeled query nucleotide; (b) providing an error-correcting polymerase comprising at least two heterologous domains, wherein a first domain that is a sequence-non-specific nucleic-acid-binding domain is joined to a second domain that is a polymerase domain, wherein the sequence non-specific nucleic-acid-binding domain: (i) binds to double-stranded nucleic acid, and (ii) enhances the processivity of the polymerase compared to an identical polymerase not having the sequence non-specific nucleic-acid-binding domain fused to it; (c) incubating the assay under conditions in which the probe is extended by the polymerase, wherein the labeled query nucleotide is cleaved from the probe when mismatched with the query sequence; and (d) detecting the amount of cleaved probe or cleaved label.
  • In another embodiment, the probe oligonucleotide is one of two primers in a polymerase chain reaction.
  • The target nucleic acid can be obtained using a PCR performed with two unlabeled primers, wherein the query sequence is not present in either of the two primers; and further, wherein the PCR reaction is contacted with the probe oligonucleotide during amplification. The 3′ query nucleotide can also be labeled with a quencher.
  • In another embodiment, the oligonucleotide probe can be complementary to a region in the amplicon that does not comprise the two primers. Additionally, the method can be performed using with a second probe oligonucleotide. The method of claim 1, further comprising a second probe oligonucleotide.
  • The 3′ end label of the assay can be labeled with a fluorescent label and the extended product is then assayed for incorporation of the fluorescent label. The 3′ end can also be labeled with a fluorescent quenching molecule and the extended product can be assayed for loss of the quencher. Alternatively, the extended product can be detected by electrophoresis and determining the presence of a fluorescent band corresponding to the extended product.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • FIG. 1 shows an agarose gel of reaction products from an assay that shows that the error-correcting enzymes Pfu and PfS efficiently correct mismatched labeled bases during PCR amplification.
  • FIG. 2 shows fluorescent intensity traces (electropherograms) for Taq and PfS reactions.
  • DETAILED DESCRIPTION OF THE INVENTION
  • Definitions
  • “Enhances” in the context of an enzyme refers to improving the activity of the enzyme, e.g., increasing the amount of product per unit enzyme per unit time.
  • “Fused” refers to linkage by covalent bonding.
  • “Heterologous”, when used with reference to portions of a protein, indicates that the protein comprises two or more domains that are not found in the same relationship to each other in nature. Such a protein, e.g., a fusion protein, contains two or more domains from unrelated proteins arranged to make a new functional protein.
  • “Join” refers to any method known in the art for functionally connecting protein domains, including without limitation recombinant fusion with or without intervening domains, intein-mediated fusion, non-covalent association, and covalent bonding, including disulfide bonding; hydrogen bonding; electrostatic bonding; and conformational bonding, e.g., antibody-antigen, and biotin-avidin associations.
  • A “polymerase” can include an entire enzyme or a catalytic domain.
  • An “improved polymerase” includes a sequence-non-specific double-stranded DNA binding domain joined to the polymerase or polymerase domain. An “unimproved polymerase” or “unmodified polymerase” is a polymerase that does not have a sequence-non-specific double-stranded DNA binding domain. “Improved polymerases” are described, for example in WO01/92501.
  • “Domain” refers to a unit of a protein or protein complex, comprising a polypeptide subsequence, a complete polypeptide sequence, or a plurality of polypeptide sequences where that unit has a defined function. The function is understood to be broadly defined and can be ligand binding, catalytic activity or can have a stabilizing effect on the structure of the protein.
  • “Error-correcting activity” of a polymerase or polymerase domain refers to the 3′ to 5′ exonuclease proofreading activity of a template-specific nucleic acid polymerase whereby nucleotides that do not form Watson-Crick base pairs with the template are removed from the 3′ end of an oligonucleotide, i.e., a strand being synthesized from a template, in a sequential manner. Examples of polymerases that have error-correcting activity include polymerases from Pryococcus furiosus, Thermococcus litoralis, and Thermotoga maritima.
  • “Processivity” refers to the ability of a nucleic acid modifying enzyme to remain attached to the template or substrate and perform multiple modification reactions. Typically “processivity” refers to the number of reactions catalyzed per binding event.
  • “Sequence-non-specific nucleic-acid-binding domain” refers to a protein domain which binds with significant affinity to a nucleic acid, for which there is no known nucleic acid which binds to the protein domain with more than 100-fold more affinity than another nucleic acid with the same nucleotide composition but a different nucleotide sequence.
  • “Thermally stable polymerase” as used herein refers to any enzyme that catalyzes polynucleotide synthesis by addition of nucleotide units to a nucleotide chain using DNA or RNA as a template and has an optimal activity at a temperature above 45° C.
  • The term “amplification reaction” refers to any in vitro means for multiplying the copies of a target sequence of nucleic acid. Such methods include but are not limited to polymerase (PCR), DNA ligase, (LCR), QβRNA replicase, and RNA transcription-based (TAS and 3SR) amplification reactions.
  • “Amplifying” refers to a step of submitting a solution to conditions sufficient to allow for amplification of a polynucleotide if all of the components of the reaction are intact. Components of an amplification reaction include, e.g., primers, a polynucleotide template, polymerase, nucleotides, and the like. The term “amplifying” typically refers to an “exponential” increase in target nucleic acid. However, “amplifying” as used herein can also refer to linear increases in the numbers of a select target sequence of nucleic acid.
  • The term “amplification reaction mixture” refers to an aqueous solution comprising the various reagents used to amplify a target nucleic acid. These include enzymes, aqueous buffers, salts, amplification primers, target nucleic acid, and nucleoside triphosphates. Depending upon the context, the mixture can be either a complete or incomplete amplification reaction mixture
  • “Polymerase chain reaction” or “PCR” refers to a method whereby a specific segment or subsequence of a target double-stranded DNA, is amplified in a geometric progression. PCR is well known to those of skill in the art; see, e.g., U.S. Pat. Nos. 4,683,195 and 4,683,202; and PCR Protocols: A Guide to Methods and Applications, Innis et al., eds, 1990; Sambrook and Russell, MOLECULAR CLONING, A LABORATORY MANUAL (3rd ed. 2001); and CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (Ausubel et al., eds., John Wiley & Sons, Inc. 1994-1997, 2001 version).
  • “Long PCR” refers to the amplification of a DNA fragment of 5 kb or longer in length. Long PCR is typically performed using specially-adapted polymerases or polymerase mixtures (see, e.g., U.S. Pat. Nos. 5,436,149 and 5,512,462) that are distinct from the polymerases conventionally used to amplify shorter products.
  • A “primer” refers to a polynucleotide sequence that hybridizes to a sequence on a target nucleic acid and serves as a point of initiation of nucleic acid synthesis. Primers can be of a variety of lengths and are often less than 50 nucleotides in length, for example 12-25 nucleotides, in length. The length and sequences of primers for use in PCR can be designed based on principles known to those of skill in the art, see, e.g., Innis et al., supra.
  • A “capture oligonucleotide” refers to an oligonucleotide attached to a discrete location, which is used for hybridizing to polynucleotides present in solution and causing them to remain in association with the discrete location.
  • An “oligonucleotide” refers to natural or synthetic chemical substances that are capable of hybridizing with polynucleotides, or otherwise substituting for natural polynucleotides in enzymatic reactions. Oligonucleotides include polymers containing non-natural monomers such as modified bases and peptide nucleic acid (PNA) monomers.
  • A “probe” refers to a polynucleotide sequence capable of hybridization to a polynucleotide sequence of interest and allows for the detecting of the polynucleotide sequence of choice. For example, “probes” can comprise polynucleotides linked to fluorescent or quenching reagent, thereby allowing for the detection of these reagents.
  • The term “subsequence” refers to a sequence of nucleotides that are contiguous within a second sequence but does not include all of the nucleotides of the second sequence.
  • A “target” or “target sequence” refers to a single or double stranded polynucleotide sequence sought to be amplified in an amplification reaction. Two target sequences are different if they comprise non-identical polynucleotide sequences.
  • A “temperature profile” refers to the temperature and lengths of time of the denaturation, annealing and/or extension steps of a PCR reaction. A temperature profile for a PCR reaction typically consists of 10 to 60 repetitions of similar or identical shorter temperature profiles; each of these shorter profiles typically define a two step or three-step PCR reaction. Selection of a “temperature profile” is based on various considerations known to those of skill in the art, see, e.g., Innis et al., supra. In a long PCR reaction as described herein, the extension time required to obtain an amplification product of 5 kb or greater in length is reduced compared to conventional polymerase mixtures.
  • Amplification or PCR “sensitivity” refers to the ability to amplify a target nucleic acid that is present in low copy number. “Low copy number” refers to 105, often 104, 103, 102, or fewer, copies of the target sequence in the nucleic acid sample to be amplified.
  • A “template” refers to a double stranded polynucleotide sequence that comprises the polynucleotide to be amplified, flanked by primer hybridization sites. Thus, a “target template” comprises the target polynucleotide sequence flanked by hybridization sites for a 5′ primer and a 3′ primer.
  • The term “query” position refers to the target polymorphic nucleotide or other polymorphism targeted by an assay of the invention.
  • “Multiplex amplification” refers to amplification of multiple polynucleotide fragments in the same reaction (see, e.g., PCR PRIMER, A LABORATORY MANUAL (Dieffenbach, ed. 1995) Cold Spring Harbor Press, pages 157-171.
  • A “polymorphism” is an allelic variant. Polymorphisms can include single nucleotide polymorphisms as well as simple sequence length polymorphisms. A polymorphism can be due to one or more nucleotide substitutions at one allele in comparison to another allele or can be due to an insertion or deletion.
  • A “solid support” refers to any material to which an oligonucleotide can be attached or any material that can be modified so that an oligonucleotide can be attached to it. Illustrative solid surfaces or solid supports include, e.g., nitrocellulose, nylon, glass, quartz, polystyrene, diazotized membranes (paper or nylon), silicones, polyformaldehyde, cellulose, and cellulose acetate. In addition, plastics such as polyethylene, polypropylene, polystyrene, and the like can be used. Other materials which may be employed include paper, ceramics, metals, metalloids, semiconductive materials, cermets or the like. In addition, substances that form gels can be used. Such materials include, e.g., proteins (e.g., gelatins), lipopolysaccharides, silicates, agarose and polyacrylamides. Where the solid surface or solid support is porous, various pore sizes may be employed depending upon the nature of the system.
  • Introduction
  • The invention provides an error-correction polymorphism assay PACE, for Polymorphism Assay by Correction of Errors, which is capable of robust operation from small amounts of genomic DNA and several schemes for parallelizing this assay for low-cost, high throughput operation. The assay is typically performed using an improved error-correcting polymerase that comprises a thermostable sequence-nonspecific double-stranded DNA-binding domain, e.g., Sso7d, attached to the polymerase, or a catalytic domain of the polymerase, which increases the processivity of the polymerase.
  • The description of the invention often refers to SNP assays as examples of polymorphism assays, but it will be appreciated that more complex polymorphisms can be detected by PACE. As long as enough of a labeled primer is complementary to a template sequence to allow priming, and the 3′ labeled end of the primer is complementary to one allele of a polymorphism, but not complementary to another allele, then PACE can distinguish between those two alleles. For instance, in the case of a deletion, e.g., from 1 to approximately 5000 bases, one labeled oligonucleotide may be complementary to the undeleted DNA, with its 3′ end corresponding to the first nucleotide that is different in the deletion allele; the other labeled oligonucleotide may be identical to the first, except that the 3′ end is complementary to the sequence found in the deletion allele. Similar logic can be used to design PACE primers to detect insertions, inversions, and multi-base sequence changes.
  • Polymerases with 3′ nuclease activity are suitable for the assays. Such polymerases include Pyrococcus polymerases such as Pfu, Pho, Pab, Pko, Pgl etc. and Thermococcus polymerases such as Tli (Vent), which are sufficiently thermostable to be suitable for PCR. Other polymerases that are not thermostable may also be used. For example, E. coli PolA has 3′ to 5′ exonuclease activitiy and could be used in an embodiment where the error correcting step is not performed at high termperatures. Engineered polymerases with 3′ nuclease activity that have at least 60% amino acid similarity to any natural error-correcting polymerase may also be used. Typically, these polymerases are modified by fusion with thermostable sequence-nonspecific double-stranded DNA-binding proteins such as Sso7d for use in the assay.
  • In a particular embodiment, the polymerase is a fusion of Sso7d to the C-terminus of Pfu polymerase, an enzyme referred to as Pfu-Sso7d or “PfS”. Example 1 shows that PfS performs an error-correcting assay including amplification directly from genomic DNA of low copy number templates in circumstances where Pfu does not work.
  • Example 2 shows that amplification with PfS distinguishes two different templates with a single nucleotide difference between them, as well as a 50:50 mixture of the two.
  • PACE Assays
  • This invention uses the error-correcting SNP assay for parallel methods of scoring single nucleotide polymorphisms, by modifying it so that it can be highly multiplexed. Rather than multiplexing by increasing the number of distinguishable fluorescent colors, the multiplex reactions of the current invention use only a small number of colors in a large number of discrete locations.
  • Assay 1: Amplification in the Presence of a Labeled Array.
  • An important concept in this assay is to employ oligonucleotides attached to discrete locations, where the attachment method permits a free 3′ end to serve as a potential substrate for the 3′ nuclease activity of a polymerase. The 3′ nucleotide is labeled, and the assay as performed surveys the discrete locations to determine whether a significant fraction, i.e., more than in a negative control, of the 3′ nucleotides attached to a particular location have been clipped off.
  • A number of other features can also be incorporated to further improve the assay. These optional features include, but are not limited to, the following:
  • 1) A PCR is performed in solution, using two unlabeled oligonucleotide primers, where the query position occurs within the amplicon but is not found in either primer;
  • 2) A labeled (probe) oligonucleotide containing the labeled query position as its 3′ nucleotide is attached to a discrete surface location by a linkage that does not include the 3′ nucleotide (i.e., the 3′ nucleotide is free to participate in enzymatic reactions). For instance, the labeled oligonucleotide can be attached by a functional group on its 5′ end. The probe is long enough to hybridize to an amplicon in solution that comprises the query position. The probe is typically at least 12-14 nucleotides in length, but can be longer, e.g., 25-30 nucleotides in length depending on the TM. As appreciated by one of skill in the art, new technologies, e.g., minor groove binders (MGB) from Synthetic Genetics can increase the affinity so that the probe can also be about 10 bases in length.
  • 3) The surface location is exposed to the PCR while the reaction is proceeding. When the unlabeled amplicon reaches sufficient concentration, it will anneal with the probe oligonucleotide, allowing the probe oligonucleotide to be extended either with or without error-correction of its 3′ end.
  • 4) The discrete surface location may be on any solid support. Typically, the discrete location is a spot on a microarray, such as is commonly constructed on a glass slide with a flat or porous surface, or is a fluorescently-labeled bead, such as the polystyrene beads commercially available from Luminex (Austin Tex.) or which have been developed by the Quantum Dot Corporation of Hayward Calif., or such as described by M. Han et al. (“Quantum dot tagged microbeads for multiplex coding of biomolecules.” Nature Biotechnology, 19:7, 631-635, 2001).
  • 5) The label on the 3′ query nucleotide of the probe oligonucleotide is a quencher, and the corresponding fluor is attached to the probe oligo somewhere close to, e.g., within about 25 or 30 bases, preferably about 10 bases, but separate from the 3′ nucleotide. The quencher can be a non-fluorescent molecule such as DABCYL. The purpose of this is to make the unreacted probe oligonucleotide have a low fluorescence due to the quencher, so that even small increases in fluorescence, resulting from a small amount of clipping of the 3′ nucleotide, will be detectable.
  • 6) Specificity of the assay is increased by making the probe complementary to an internal sequence. Specifically, the unlabeled amplification primers (optional feature 1) can be designed so as to amplify a significant amount of sequence not present in either primer—for instance, at least 3 and as many as 15 or more bases, e.g., 50, 100, 500, 1000, 5000 or more bases. At least part of the probe, i.e., a subsequence of the probe, is complementary to the sequence not present in either primer. The subsequence of the probe not complementary to either primer is increased until the probe oligonucleotides are functionally specific for a true template-derived amplicon, and not affected by a primer-dimer or similar artifact. Taqman-type cleavage of the probe is not an issue if a polymerase with no 5′-3′ exonuclease activity is used (e.g., Pyrococcus-type polymerases). The probe sequence is designed to discriminate between other amplicons that may be present in the reaction, i.e., it will hybridize to one amplicon and not to the others. Exemplary hybridization conditions are typically compatible with amplification reactions, e.g., hybridization can be performed at 50 mM KCl, 10 mM Tris pH8.5, 1.5 mM Mg++ at a temperature that is usually between 60° C. and 72° C.
  • 7) At least two probe oligonucleotides are employed. They can be in a single discrete location and distinguished from each other by means of color, or they can be in separate discrete locations.
  • 8) For highest confidence, four probe oligonucleotides are present, corresponding to all four possible bases in the query position. In general two bases will be expected and two will be unexpected. The unexpected bases serve as controls for the efficiency of the assay, and to score rare individuals with unexpected alleles.
  • 9) The assays can be highly multiplexed, so that at least dozens, and perhaps many thousands of different assays can be performed together in the same solution. In parallel assays, the probe oligonucleotides are designed to have about the same TM using algorithms well known to those of skill in the art. Typically, the probes have a TM within 10° C. of one another, more often between 5° C. or 2° C. of one another.
  • Not all of these elements must be present for the invention to be workable. In a preferred embodiment, the assay differs from the Genome Therapeutics protocol by at least elements 1, 2, 3, and 4. The assay can be further improved by addition of elements 5, 6, 7, 8, and 9 singly or in combinations.
  • Assay 2: Post-Amplification Readout using Hybridization to an Array
  • In this assay version, amplifications are performed, typically directly from genomic DNA, and the assay is read out, i.e., the results are determined, by hybridization to probes fixed to a discrete location on a solid support, e.g., a microarray. In general, this assay is performed by PCR amplification, where one of the primers has the polymorphic sites, e.g., an SNP site, at its 3′ end, and that base contains a fluorescent label. Read-out is accomplished by hybridizing the amplified DNA to an unlabelled microarray and determining the amount of fluorescent signal at particular known locations relative to controls. In general, such an assay would be multiplexed.
  • Additional embodiments of this assay include, but are not limited to, the following:
  • 1) For a given polymorphism, e.g., an SNP, more than one 3′ base-labeled oligonucleotide is used, with each different base having a different color label. Only those bases corresponding to polymorphic alleles present in the sample will be extended at any significant rate, and thus only colors corresponding to those bases will be significantly incorporated into the amplified DNA. Therefore, after hybridization, the colors present at an array site expected to hybridize to a particular product correspond to the polymorphism alleles present in the original sample. In this case, each allele and heterozygotes are distinguishable by the ratios of the amount of each color present, and are all clearly distinguishable from reaction failures, which have no or very little color present.
  • 2) For hybridization to be specific to amplified product, it must depend at least in large part on sequences not contained in the labeled input primer. Specific hybridization may be accomplished in at least two ways. A) The amplicon may contain some sequence, preferably at least 10 bases, that is not contained in either of the two PCR primers, and hybridization to the array may depend on the presence of this sequence. Amplicons may be large, with reliable amplification of at least 5 kb being known in the art. Therefore it should always be possible to find a set of sufficiently non-cross-hybridizing sequences sufficiently close to a polymorphic site, e.g., an SNP site, so that specific arrays may be constructed. B) A set of pre-determined hybridization sites may be incorporated into the non-labeled primers for each amplicon, and these predetermined sites may be used as a basis for differential hybridization to an array. This method allows the use of standard arrays for many different polymorphism-scoring assays, through the incorporation of the same set of pre-determined hybridization sites into the unlabeled oligonucleotides of each different assay.
  • An advantage of method A is that it assures that only amplification products corresponding to the correct locus will be contribute to the hybridization signal. In practice, method B can be sufficiently specific, and can be justified by the cost advantage of using standard arrays. Methods A and B may also be used in combination in a single experiment.
  • 3) Other types of fluorescent reporter configurations may be used. Arrays may be labeled with a fluor, and the read-out may be on the basis of FRET between the array and the amplicon. Oligonucleotides may be double-labeled with two fluors or a fluor and a quencher, and readout may depend on changes in fluorescence due to removal of one moiety.
  • Assay 3: Post-Amplification Readout using Electrophoresis
  • This assay is similar to Assay 2, with a different readout mechanism. Amplifications are performed, preferably directly from genomic DNA, and the assay is read out by electrophoretic analysis with fluorescent detection. In general, this assay is performed by PCR amplification, where one of the primers has the polymorphic, e.g., a SNP site, at its 3′ end, and that base contains a fluorescent label. Electrophoretic analysis is accomplished by capillary or gel electrophoresis instruments well known in the art, intended for fluorescent automated DNA sequencing or other types of fluorescent DNA fragment analysis. In general, such an assay would be multiplexed. Additional refinements are also possible and include, but are not limited to, the following:
  • 1) For a given polymorphism, more than one 3′ base-labeled oligonucleotide is used, with each different base having a different color label. Only those bases corresponding to polymorphic, e.g., SNP, alleles present in the sample will be extended at any significant rate, and thus only colors corresponding to those bases will be significantly incorporated into the amplified DNA. Therefore, upon electrophoretic analysis, the colors present at a position corresponding to the expected size of a particular product correspond to the polymorphic alleles present in the original sample. In this case, each allele and heterozygotes are distinguishable by the ratios of the amount of each color present, and are all clearly distinguishable from reaction failures, which have no or very little color present.
  • 2) Multiple polymorphic sites, such as SNP sites, may be assayed in a single electrophoretic run by the simple expedient of adjusting the amplicon size so that each polymorphic site corresponds to a distinguishable amplicon size. This adjustment can be made by choosing the sequence of the unlabeled primer to correspond to sequences at various distances from the SNP site. In some instances, a particular primer sequence may be disfavored because of its potential for illegitimate hybridization; in this case, a different length can be chosen, or the strand of the labeled primer may be switched. A typical electrophoretic instrument such as the BaseStation (MJ Research, Waltham Mass.) can easily resolve fragments at four-base intervals to lengths greater than 1100 bases in 96 sample lanes simultaneously. If each lane contains alleles starting at 80 bases (so as to be separated from free dye breakdown products and primer-dimer artifacts) and continuing to 1100 bases, over 250,000 determinations cam be made in a four-hour run on a single instrument.
  • Assay Components
  • Oligonucleotides
  • Oligonucleotides used in the invention typically containing base-linked fluors and quenchers are well-known in the art. They can be obtained, for example, from Life Technologies (Gaithersburg, Md.), Sigma-Genosys (The Woodlands, Tex.), Genset Corp. (La Jolla, Calif.), or Synthetic Genetics (San Diego, Calif.).
  • The primers for the amplification reactions are designed according to known algorithms. Typically, commercially available or custom software will use algorithms to design primers such that that annealing temperatures are close to melting temperature. Typically, the primers are at least 12 bases, more often 15, 18, or 20 bases in length. Primers are typically designed so that all primers participating in a particular reaction have melting temperatures that are within 5° C., and most preferably within 2° C. of each other. Primers are further designed to avoid priming on themselves or each other. Primer concentration should be sufficient to bind to the amount of target sequences that are amplified so as to provide an accurate assessment of the quantity of amplified sequence. Those of skill in the art will recognize that the amount of concentration of primer will vary according to the binding affinity of the primers as well as the quantity of sequence to be bound. Typical primer concentrations will range from 0.01 μM to 0.5 μM.
  • The polymerase reactions are incubated under conditions in which the primers hybridize to the target sequences and are extended by a polymerase. As appreciated by those of skill in the art, such reaction conditions may vary, depending on the target sequence and the composition of the primer. The amplification reaction cycle conditions are selected so that the primers hybridize specifically to the target sequence and are extended. Exemplary PCR conditions for particular primer sets are provided in the examples.
  • In some cases, base-linked fluors are incorporated into the oligonucleotdies by post-synthesis modification of oligonucleotides that were synthesized with reactive groups linked to bases. One of skill will recognize that a large number of different fluorophores are available, including from commercial sources such as Molecular Probes, Eugene, Oreg. and other fluorophores known to those of skill in the art. For a general listing of useful fluorophores, see Hermanson, G. T., BIOCONJUGATE TECHNIQUES (Academic Press, San Diego, 1996). Thus, each probe will fluoresce at a different wavelength and can be individually detected without interference from the other probes.
  • Fluorescence-based assays can also rely for signal generation on fluorescence resonance energy transfer, or “FRET”, according to which a change in fluorescence is caused by a change in the distance separating a first fluorophore from an interacting resonance energy acceptor, either another fluorophore or a quencher. Combinations of a fluorophore and an interacting molecule or moiety, including quenching molecules or moieties, are known as “FRET pairs.” The mechanism of FRET-pair interaction requires that the absorption spectrum of one member of the pair overlaps the emission spectrum of the other member, the first fluorophore. If the interacting molecule or moiety is a quencher, its absorption spectrum must overlap the emission spectrum of the fluorophore. Stryer, L., Ann. Rev. Biochem. 47: 819-846 (1978); BIOPHYSICAL CHEMISTRY part II, Techniques for the Study of Biological Structure and Function, C. R. Cantor and P. R. Schimmel, pages 448-455 (W. H. Freeman and Co., San Francisco, U.S.A., 1980); and Selvin, P. R., Methods in Enzymology 246: 300-335 (1995). Efficient FRET interaction requires that the absorption and emission spectra of the pair have a large degree of overlap. The efficiency of FRET interaction is linearly proportional to that overlap. See Haugland, R. P. et al. Proc. Natl. Acad. Sci. USA 63: 24-30 (1969). Typically, a large magnitude of signal (i.e., a high degree of overlap) is required. FRET pairs, including fluorophore-quencher pairs, are therefore typically chosen on that basis.
  • A variety of labeled nucleic acid hybridization probes and detection assays that utilize FRET and FRET pairs are known. One such scheme is described by Cardullo et al. Proc. Natl. Acad. Sci. USA 85: 8790-8794 (1988) and in Heller et al. EP 0070685. It uses a probe comprising a pair of oligodeoxynucleotides complementary to contiguous regions of a target DNA strand. One probe molecule contains a fluorescent label, a fluorophore, on its 5′ end, and the other probe molecule contains a different fluorescent label, also a fluorophore, on its 3′ end. When the probe is hybridized to the target sequence, the two labels are brought very close to each other. When the sample is stimulated by light of an appropriate frequency, fluorescence resonance energy transfer from one label to the other occurs. FRET produces a measurable change in spectral response from the labels, signaling the presence of targets. One label could be a “quencher,” which in this application is meant an interactive moiety (or molecule) that releases the accepted energy as heat.
  • Solid Supports
  • Any solid support, including, but not limited to membrane filters, slides, microparticles and the like, may be used in the methods of the invention. In particular embodiments, microarrays are used. Labeled arrays, e.g., those used in assay 1, are constructed by attachment of separately-synthesized oligonucleotides using any of several attachment chemistries, below. Unlabeled oligonucleotides, e.g., those prepared for Assay 2, may be attached by such methods, and additionally may be synthesized directly in situ by various techniques. Such arrays are made, e.g., by Affymetrix (Santa Clara Calif.) and Rosetta Inpharmics (Kirkland Wash.).
  • Attachment Chemistries
  • Because probe oligonucleotides used, e.g., in Assay 1 must have free 3′ ends, they cannot be synthesized on the surface where they will be used by conventional phosphoramidite chemistry, which results in the 3′ end being attached to the substrate. Instead, they are synthesized separately, with a functional group, such as an amino, acrylic (Mosaic Technologies, Boston Mass.), or thiol group, on the 5′ end. Appropriate surfaces with functional groups are readily available. For example, glass slides are conventionally available with aminosilane or poly-L-lysine coatings providing amino groups. Glass slides may be modified via silane chemistry to have a reactive vinyl group, and may be coupled to an oligonucleotide containing an acrylic group via radical vinyl polymerization, for instance in the presence of acrylamide monomers. Polystyrene beads are conventionally available with carboxyl groups on their surfaces. Other types of surface groups can be obtained through conventional chemical manipulations. These functional groups can be used to link the oligonucleotides to the surface through conventional chemistries. Preferably, the oligonucleotides are attached to the discrete surface locations.
  • Multiplexing
  • Multiplexing of PCR amplification is well known in the art. The reaction described herein can be highly multiplexed. Not to be bound by theory, the reactions can be highly multiplexed for the following reasons. First, unwanted, non-specific reaction products can be kept to a minimum by primer design, use of minimal primer concentration, and close control over reaction conditions. For example, primers are designed to have about the same TM, usually within 10° C., often 5° C., or 2° C. The primers are also designed to avoid producing a PCR product by mispairing. The reaction is controlled to keep the annealing and extensions temperatures such that the primers do not prime at incorrect sites at a detectable level. Second, by incorporating element 6 of Assay 1, unwanted reaction products can be kept from substantial interference with the assay. For Assays 2 and 3, effective multiplexing may be increased by splitting an assay into several separate vessels, each with a different set of primers, and combining them for the purposes of read-out.
  • Polymerases
  • Polymerases are well-known to those skilled in the art. These include both DNA-dependent polymerases and RNA-dependent polymerases such as reverse transcriptase. At least five families of DNA-dependent DNA polymerases are known, although most fall into families A, B and C. There is little or no structural or sequence similarity among the various families. Most family A polymerases are single chain proteins that can contain multiple enzymatic functions including polymerase, 3′ to 5′ exonuclease activity and 5′ to 3′ exonuclease activity. Family B polymerases typically have a single catalytic domain with polymerase and 3′ to 5′ exonuclease activity, as well as accessory factors. Family C polymerases are typically multi-subunit proteins with polymerizing and 3′ to 5′ exonuclease activity. In E. coli, three types of DNA polymerases have been found, DNA polymerases I (family A), II (family B), and III (family C). In eukaryotic cells, three different family B polymerases, DNA polymerases α, δ, and ε, are implicated in nuclear replication, and a family A polymerase, polymerase γ, is used for mitochondrial DNA replication. Other types of DNA polymerases include phage polymerases.
  • Polymerases with 3′ to 5′ exonuclease activity are used in the invention. These include family B polymerases such as Pyrococcus polymerases such as Pfu, Pho, Pab, Pko, Pgl etc. and Thermococcus polymerases such as Tli (Vent), which are sufficiently thermostable to be suitable for PCR. Family A polymerases that have error-correcting activity may also be used, e.g., Tth. Further, in some embodiments, non-thermostable polymerases may be used. For example, E. coli PolI has 3′ to 5′ exonuclease activitiy and could be used in an embodiment where the error correcting step is not performed at high temperatures.
  • In some embodiments, it is advantageous to use polymerases having enhanced processivity, “improved polymerases”. Examples of these include those described in WO01/92501. These improved polymerases exhibit enhanced processivity due to the presence of a sequence-non-specific double-stranded DNA binding domain that is joined to the polymerase or the enzymatic domain of the polymerase). Often the binding domain is from a thermostable organism and provides enhanced activity at higher temperatures, e.g., temperatures above 45° C. For example, Sso7d and Sac7d are small (about 7,000 kd MW), basic chromosomal proteins from the hyperthermophilic archaeabacteria Sulfolobus solfataricus and S. acidocaldarius, respectively (see, e.g., Choli et al., Biochimica et Biophysica Acta 950:193-203, 1988; Baumann et al., Structural Biol. 1:808-819, 1994; and Gao et al, Nature Struc. Biol. 5:782-786, 1998). These proteins bind DNA in a sequence-independent manner and when bound, increase the TM of DNA by up to 40° C. under some conditions (McAfee et al., Biochemistry 34:10063-10077, 1995). These proteins and their homologs are often used as the sequence-non-specific DNA binding domain in improved polymerase fusion proteins.
  • Often, in embodiments in which long PCR is necessary, improved polymerases are used. These polymerases can be used to obtain long, i.e., 5 kb, often 10 kb, or greater in length, PCR products. “Long PCR” using these improved polymerases can be performed using extension times that are reduced compared to prior art “long PCR” polymerase and/or polymerase mixtures. Extension times of less than 30 seconds per kb, often 15 seconds per kb, can be used to amplify long products in PCR reactions using the improved polymerases. Furthermore, these modified polymerases also exhibit increased sensitivity.
  • Prior-art non-error-correcting polymerases such as Taq polymerase are capable of amplifying DNA from very small input copy concentrations, such as, in the extreme, 10 copies per ml. However, because of the low fidelity of such polymerases, products cloned from such amplifications are likely to contain introduced mutations.
  • Prior-art error-correcting polymerases such as Pfu copy DNA with higher fidelity than Taq, but are not capable of amplifying DNA from small input copy concentrations. The hybrid error-correcting polymerases of the invention exhibit much higher processivity while retaining error-correcting activity and thereby provide both sensitivity and fidelity in amplification reactions.
  • Reactions
  • Typical reactions may be set up as follows:
  • Assay 1: Genomic DNA from an individual to be tested is mixed with a PCR mixture containing an appropriate polymerase and one unlabelled primer pair for each locus to be tested. The reaction mixture is placed into a vessel and put into contact with surfaces to which probe oligonucleotides are attached. The combination of a vessel and surfaces for probe attachment can be satisfied in several ways: for instance, a standard plastic thermal cycling reaction vessel containing color-coded polystyrene beads to which probes are attached; or a glass slide with probes attached in discrete spots, and an appropriate chamber or cover for containing the reaction volume. The vessel is then thermally cycled to allow the PCR and assay to proceed.
  • Assays 2 and 3: Genomic DNA from an individual to be tested is mixed with a PCR mixture containing an appropriate polymerase and one primer pair for each locus to be tested, where a primer pair consists of one labeled and one unlabeled primer. After amplification, all separate amplification tubes are combined, and the products are denatured and analyzed by the method of choice.
  • Reaction variations—At least some amplification may take place before the solution containing DNA to be tested is exposed to the surface with attached probe oligonucleotide. An amplification other than PCR, such as transcription-mediated amplification (TMA), strand displacement amplifcation (SDA), nucleic acid sequence-based amplification (NASBA), LCR, oligonucleotide ligation assay (OLA), etc., may be employed. In this case, concurrent amplification may not be used.
  • Readout—Fluorescence may be quantified in the discrete locations by any of several methods. Numerous commercially-available instruments, such as those manufactured by Axon Instruments (Foster City, Calif.) and Applied Precision (Issaquah, Wash.) can quantify fluorescence from spots on the surface of a flat substrate. Fluorescent-coded beads can be read using flow-cytometry-type instrumentation, such as that manufactured by Luminex (Austin, Tex.). Other optical properties besides color of fluorescent emissions can be used to distinguish reaction products—for instance, time-resolved fluorescence.
  • Interpretation—For the case where the query position of the probe contains a quencher, an increase in fluorescence, relative to a control, from a discrete location in a particular color indicates that the 3′ nucleotide of the probe corresponding to that location and color does not match at least some of the amplicons present in the solution. For a homozygote for a particular SNP allele, the expected pattern is a large increase in fluorescence for each probe with a 3′ mismatch. For a heterozygote, all probes are expected to have an increase in fluorescence, but those corresponding to the SNP alleles that are actually present will show a smaller increase in fluorescence due to the fact that the probes can be extended, and thus protected from nuclease activity, if they anneal to a matched amplicon.
  • All publications, patents, and patent applications cited in this specification are herein incorporated by reference as if each individual publication or patent application were specifically and individually indicated to be incorporated by reference.
  • Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.
  • EXAMPLES
  • The following examples are provided by way of illustration only and not by way of limitation. Those of skill will readily recognize a variety of non-critical parameters that could be changed or modified to yield essentially similar results.
  • Example 1
  • Modified Error-Correcting Enzymes are Superior to Unmodified Error-Correcting Enzymes in Amplifying DNA from Low Copy Number Templates.
  • The efficiency with which modified and unmodified error-correcting polymerases can amplify products from small numbers of input template copies was tested using “real-time” PCR. PCR was performed in the presence of the double-stranded-DNA-specific fluorescent dye SYBR Green I (Molecular Probes, Eugene Oreg.) in a DNA Engine Opticon continuous fluorescence detection thermal cycling system (MJ Research, Waltham Mass.). A 57 bp portion of the human cytochrome P450 gene CYP2D6 (GenBank Accession # M33388, nucleotides 3265-3322) was amplified using primers F1 (forward) and R1 (reverse) from a template containing a perfect match to both primers. The number of thermal cycles required for the fluorescence to reach a threshold value (threshold cycle, or Ct) was recorded. The Ct value represents the number of cycles required to generate a detectable amount of DNA. A “detectable” amount of DNA is at least 2 standard deviations, and usually 5 or more standard deviations above the background noise level. In the conditions employed in this example, a detectable amount corresponds to approximately 1 ng of DNA. An efficient polymerase may be able to produce a detectable amount of DNA in a smaller number of cycles by more closely approaching the theoretical maximum amplification efficiency of PCR. Accordingly, a lower Ct value reflects a greater amplification efficiency for the enzyme. The enzymes tested were Pfu (Stratagene, La Jolla Calif.) and PfS, a fusion of Sso7d to the carboxy terminus of Pfu, as described in the co-pending U.S. application Ser. No. 09/870,353. Each enzyme was tested over a range of concentrations from 40 units/ml to 5 units/ml. PfS was found to require between ¼ and 1/10 as many units as Pfu for efficient amplification. Each enzyme was used in its optimal buffer.
    Primer F1: AGG CGC TTC TCC GTG (SEQ ID NO:1)
    Primer R1: CTC CAG CGA CTT CTT GC (SEQ ID NO:2)

    Reaction Conditions
    • 20 μl reactions contained:
    • 0.5× SYBR Green I
    • 10 mM KCl (Pfu) or 50 mM KCl (PfS)
    • 2 mM MgCl2
    • 10 mM Tris-Cl, pH 8.75
    • 200 mM each dNTP
    • 300 μM each primer
    • Enzyme and template amounts as listed below.
      Thermal Cycling Conditions were:
    • 1 94° C. 2 minutes
    • 2 94° C. 10 seconds
    • 3 60° C. 15 seconds
    • 4 72° C. 30 seconds, take fluorescence reading
    • 5 Go to step 2, 45 cycles
  • 6 72° C. 10 minutes
    TABLE 1
    Effect of enzyme type and amount on threshold cycle
    Input Template Copy No.
    107 106 105 104 103 102 10
    PfS, Units/ml
    40 16.3 20.5 23.0 26.3 29.5 30.5 33.1
    20 16.9 20.5 22.4 26.1 29.6 26.5 35.0
    10 17.1 20.0 21.7 26.0 29.4 32.2 34.5
     5 20.2 23.8 24.6 31.0 34.2 43.3 41.2
    Pfu, Units/ml
    40 16.1 21.9 22.7 27.2 29.5 35.6 37.0
    20 26.6 28.6 35.7 36.0 45.7
    10 25.4
     5 40.2
  • PfS amplified the template with high efficiency at enzyme concentrations from 10-40 U/ml at all input DNA copy numbers, down to 10 copies. PfS showed slightly less efficient amplification at 5 U/ml. By contrast, Pfu only amplified the template efficiently at 40 U/ml, and even then, only down to an input copy number of 1000 copies. At lower enzyme or template concentrations, amplification was inefficient, and in many cases did not result in a detectable product generated within the 46 cycles of the experiment.
  • Example 2
  • The Error-Correcting Enzymes Pfu and PfS Efficiently Correct Mismatched Labeled Bases during PCR Amplification.
  • PCR was performed using a 3′ base-labeled primer in conditions where it had either a perfect match with the template, or a 3′ single-base mismatch with the template. Primer F2 was the base-labeled primer, with the same sequence as primer F1 except the 3′ G (query position) is replaced with a C with a carboxyfluorescein (FAM) dye attached at the 5 position through a linker. 106 copies of plasmid clones with either a G or a C in the polymorphic position were used as templates. The reverse primer, R2, was designed to produce a 475-base amplicon. Enzymes used were Taq Gold (ABI, Foster City Calif.), PfS, and Pfu. Six PCRs were performed, with all combinations of the three enzymes and two templates.
  • Conditions were similar to those from example 1. Taq Gold reactions used the commercially-supplied 2× master mix. 2× master mixes were also prepared for Pfu and PfS, which were each used at 20 U/ml.
  • Each 20 μl Reaction Contained:
    • 7 μl ddH2O
    • 2 μl 10× primers (final 0.3 μM each)
    • 1 μl (10ˆ6 copies/μl cut plasmid template DNA) 10 μl 2× master mix
      Cycling Program:
    • 1: 94° C. forever (insert sample plate while the block has reached 94° C., then skip to step 2.
    • 2: 94° C. 2 min
    • 3: 96° C. 10 s
    • 4: 55° C. 15 s
    • 5: 74° C. 40 s
    • 6: go to step 2 for 29 times
  • 7: 72° C. for 10 min
    Primer F2: AGG CGC TTC TCC GTC (FAM) (SEQ ID NO:3)
    Primer R2: ATG TCC TTT CCC AAA CCC AT (SEQ ID NO:4)

    Results:
  • FIG. 1 shows an aliquot of each reaction run on an agarose gel and stained with ethidium bromide. Products were produced in all reactions, though there was a lower yield for the mismatch condition with Taq and Pfu. The overall yield was highest with PfS.
  • Products of the six reactions were diluted to equalize the concentrations, then equal amounts were loaded on six lanes of a BaseStation fluorescent electrophoretic analyzer. Results are shown in FIG. 2. Taq Polymerase produced a labeled band in both match and mismatch conditions, indicating that, as expected, the enzyme was not capable of correcting a mismatch, but simply extended the mismatched base. Both PfS and Pfu produced a labeled band in the matched condition, showing that they were capable of extending from the 3′ end of the labeled base. However, both enzymes produced an essentially unlabeled band in the mismatch condition, demonstrating that they are capable of very efficiently correcting the 3′ labeled base before extending the primer.
  • Example 3
  • PCR was performed using a 3′ base-labeled primer in conditions where it had either a perfect match with the template, or a 3′ single-base mismatch with the template. Two labeled primers were used: F2 and F3 were base-labeled, with the same sequence as primer F1 except the 3′ G (query position) is replaced with a C with a carboxyfluorescein (FAM) dye attached at the 5 position through a linker o or a T labeled with Bodipy R6G (BR6G) (Molecular Probes, Eugene Oreg.) linked to the T methyl group via a 6-carbon linker. 106 copies of plasmid clones with either a G or a C in the polymorphic position were used as templates. The reverse primer, R2, was designed to produce a 475-base amplicon. Enzymes used were Taq Gold (ABI, Foster City Calif.), PfS, and Pfu. Twenty seven PCRs were performed, with all combinations of the three enzymes, two primers singly and in combination, and two templates singly and in combination.
  • Primer F3 was poorly labeled (only about 7% of molecules were dye-labeled) so it was used at a higher concentration than primer F2 to compensate for that difference.
    Primer F2: AGG CGC TTC TCC GTC (FAM) (SEQ ID NO:3)
    Primer F3: AGG CGC TTC TCC GTT (R6G) (SEQ ID NO:5)
    Primer R2: ATG TCC TTT CCC AAA CCC AT (SEQ ID NO:3)
  • Conditions were similar to those from example 1. Taq Gold reactions used the commercially-supplied 2× master mix. 2× master mixes were also prepared for Pfu and PfS, which were each used at 20 U/ml.
  • Each 20 μl Reaction Contained:
    • 7 μl ddH2O
    • 2 μl 10× primers (final 0.1 μM F2, 1.5 μM F3, and 0.3 μM R2 each)
    • 1 μl (106 copies/μl cut plasmid template DNA) (cut template)
    • 10 μl 2× master mix
      Cycling Program:
    • 1: 94° C. forever (insert sample plate while the block has reached 94° C., then skip to step 2.
    • 2: 94° C. 2 min
    • 3: 96° C. 10 s
    • 4: 55° C. 15 s
    • 5: 74° C. 40 s
    • 6: go to step 2 for 29 times
    • 7: 72° C. for 10 min
  • PCR products were analyzed electrophoretically on a BaseStation fluorescent electrophoretic analyzer (MJ Research, Waltham Mass.). Fluorescence intensity traces for each lane were baseline subtracted, but no attempt was made to perform a color separation deconvolution. Table 2 summarizes the results. The numbers presented in Table 2 are the heights of peaks corresponding to a 475-base fragment. If no peak was detectable, no number is given. Channel 1 is about twice as sensitive to FAM as BR6G, while channel 2 is about twice as sensitive to BR6G as FAM. So a pure peak of one dye will result in a peak in its corresponding channel and a peak of half that height in the other channel.
  • Results:
  • Although the results are somewhat skewed by the poor labeling of the T oligo and the corresponding compensation by concentration adjustment, it is clear that the assay works well. In particular, Table 2 shows that for the case where a mixture of the C and T primers is used, the reactions employing PfS can clearly distinguish between templates consisting of 100% A, 100% G, and a 50/50 mixture of A and G. These three cases correspond to a valuable use of the assay in distinguishing between two homozygotes and a heterozygote.
  • In FIG. 2, all three panels are electropherograms of reactions from Example 3 employing mixed C and T labeled primers. Channel 1 signal is in black and channel 2 signal is in grey. The top panel was from Lane 12, the reaction with G template, and channel 1 signal is double that from channel 2, indicating a pure C peak. The center panel was from Lane 15, the reaction with A template, and channel 2 signal is double that from channel 1, indicating a pure T peak. The bottom panel was from Lane 18, the reaction with mixed Aand G template, and channel 1 and channel 2 signals are approximately equal, indicating a both a C and a T peak. Further, in the bottom pane, the channel 1 and 2 signals are not coincident, corresponding to a small mobility difference between the two dyes, further reinforcing the conclusion that both labeled peaks are present.
  • PfS performed much better that Pfu in this example, although it is expected that with a high input copy number and a sufficiently high enzyme concentration, Pfu would perform adequately.
    TABLE 2
    Enzyme Primer Template Channel 1 Channel 2 Base
    Taq C G 2000 1000 C
    Taq T G
    Taq C + T G
    Taq C A 900 400 C
    Taq T A 35 70 T
    Taq C + T A 20 30 T
    Taq C G + A 2000 1000 C
    Taq T G + A
    Taq C + T G + A 40 80 T
    PfS C G 3200 1800 C
    PfS T G
    PfS C + T G 410 210 C
    PfS C A 2800 1500 C
    PfS T A 150 550 T
    PfS C + T A 100 400 T
    PfS C G + A 3000 1500 C
    PfS T G + A 150 400 T
    PfS C + T G + A 300 360 C/T
    Pfu C G 1800 800 C
    Pfu T G
    Pfu C + T G
    Pfu C A 760 360 C
    Pfu T A
    Pfu C + T A
    Pfu C G + A 2000 1000 C
    Pfu T G + A
    Pfu C + T G + A

Claims (19)

1. A method of identifying a polymorphism using an error-correcting assay, the method comprising:
(a) contacting a target nucleic acid comprising a query sequence with a probe oligonucleotide under conditions in which the probe specifically hybridizes to the target nucleic acid, wherein the 3′ nucleotide of the probe is a labeled query nucleotide and is attached to a discrete surface location;
(b) providing an error-correcting polymerase;
(c) incubating the assay under conditions in which the probe is extended by the polymerase, wherein the labeled query nucleotide is cleaved from the probe when mismatched with the query sequence; and
(d) detecting the amount of probe in the discrete location that has been labeled.
2. The method of claim 1, wherein the polymerase is a family B polymerase.
3. The method of claim 2, wherein the family B polymerase is a Pyrococcus polymerase.
4. The method of claim 1, wherein the target nucleic acid is a PCR amplicon obtained using a PCR reaction performed with two unlabeled primers, wherein the query sequence is not present in either of the two primers.
5. The method of claim 4, wherein the target nucleic acid is obtained using a PCR reaction performed with two unlabeled primers, wherein the query sequence is not present in either of the two primers; and further, wherein the PCR reaction is contacted with the probe oligonucleotide during amplification.
6. The method of claim 5, wherein the oligonucleotide probe is complementary to a region in the amplicon that does not comprise the two primers.
7. The method of claim 1, wherein the discrete surface location is on a microarray.
8. The method of claim 1, wherein the 3′ query nucleotide is labeled with a quencher.
9. The method of claim 1, further comprising a second probe oligonucleotide.
10. A method of identifying a polymorphism using an error-correcting assay, the method comprising:
(a) contacting a target nucleic acid comprising a query sequence with an oligonucleotide probe under conditions in which the probe specifically hybridizes to the target nucleic acid, wherein the 3′ nucleotide of the probe is a labeled query nucleotide;
(b) providing an error-correcting polymerase;
(c) incubating the assay under conditions in which the probe is extended by the polymerase thereby providing an extended product, wherein the labeled query nucleotide is cleaved from the probe when mismatched with the query sequence;
(d) providing a capture oligonucleotide attached to a discrete location and complementary to the extended product;
(e) hybridizing the extended product to the capture oligonucleotide and
(f) detecting the amount of label at the discrete location.
11. The method of claim 10, wherein the 3′ end of is labeled with a fluroescent label.
12. The method of claim 10, wherein the capture oligonucleotide is in a microarray.
13. The method of claim 10, wherein the 3′ end is labeled with a fluorescent quenching molecule.
14. The method of claim 13, further wherein the extended product is hybridized to a capture oligonucleotide that is labeled with a fluor.
15. The method of claim 10 wherein the polymerase is a family B polymerase.
16. The method of claim 10, wherein the family B polymerase is a Pyrococcus polymerase.
17. A method of identifying a polymorphism using an error-correcting assay, the method comprising:
(a) contacting a target nucleic acid comprising at least two query sequences with at least two oligonucleotide probes under conditions in which the probes specifically hybridize to the target nucleic acid at different sites, wherein the 3′ nucleotides of the probes are labeled query nucleotides, and further, wherein the labels are different;
(b) providing an error-correcting polymerase;
(c) incubating the assay under conditions in which the probes are extended by the polymerase thereby providing extended products, wherein the labeled query nucleotides are cleaved from the probes when mismatched with the query sequences;
(d) separating the extended products electrophoretically; and
(e) detecting the amount of label in the extended products.
18. The method of claim 17, wherein the polymerase is a family B polymerase.
19. The method of claim 18, wherein the family B polymerase is a Pyrococcus polymerase.
US11/521,754 2001-11-28 2006-09-15 Parallel polymorphism scoring by amplification and error correction Abandoned US20070009954A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/521,754 US20070009954A1 (en) 2001-11-28 2006-09-15 Parallel polymorphism scoring by amplification and error correction

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33403201P 2001-11-28 2001-11-28
US10/306,828 US7163790B2 (en) 2001-11-28 2002-11-27 Parallel polymorphism scoring by amplification and error correction
US11/521,754 US20070009954A1 (en) 2001-11-28 2006-09-15 Parallel polymorphism scoring by amplification and error correction

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/306,828 Continuation US7163790B2 (en) 2001-11-28 2002-11-27 Parallel polymorphism scoring by amplification and error correction

Publications (1)

Publication Number Publication Date
US20070009954A1 true US20070009954A1 (en) 2007-01-11

Family

ID=23305282

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/306,828 Expired - Fee Related US7163790B2 (en) 2001-11-28 2002-11-27 Parallel polymorphism scoring by amplification and error correction
US11/521,754 Abandoned US20070009954A1 (en) 2001-11-28 2006-09-15 Parallel polymorphism scoring by amplification and error correction

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/306,828 Expired - Fee Related US7163790B2 (en) 2001-11-28 2002-11-27 Parallel polymorphism scoring by amplification and error correction

Country Status (6)

Country Link
US (2) US7163790B2 (en)
EP (1) EP1456409B1 (en)
AT (1) ATE458832T1 (en)
AU (1) AU2002351193A1 (en)
DE (1) DE60235491D1 (en)
WO (1) WO2003046208A2 (en)

Cited By (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020142326A1 (en) * 2000-11-30 2002-10-03 Coull James M. Methods and compositions for sorting and/or determining organisms
US20020177144A1 (en) * 1997-12-30 2002-11-28 Jose Remacle Detection and/or quantification method of a target molecule by a binding with a capture molecule fixed on the surface of a disc
US20030059822A1 (en) * 2001-09-18 2003-03-27 U.S. Genomics, Inc. Differential tagging of polymers for high resolution linear analysis
US20030096321A1 (en) * 1999-05-19 2003-05-22 Jose Remacle Method for the identification and/or the quantification of a target compound obtained from a biological sample upon chips
US20030104405A1 (en) * 2001-02-09 2003-06-05 Sapporo Breweries Limited Method of differentiating beer yeast
US20030143581A1 (en) * 2001-07-20 2003-07-31 Stefan Franzen Light addressable electrochemical detection of duplex structures
US20030207289A1 (en) * 2001-09-04 2003-11-06 Hodge Timothy A. Detection of genetic sequences using a bipartite probe
US20030215891A1 (en) * 2000-07-01 2003-11-20 Ralf Bickel Method for the qualitative and/or quantitative detection of molecular interactions on probe arrays
US20040009612A1 (en) * 2002-05-28 2004-01-15 Xiaojian Zhao Methods and apparati using single polymer analysis
US20040029160A1 (en) * 2002-05-24 2004-02-12 Ramon Eritja Parallel stranded duplexes of deoxyribonucleic acid and methods of use
US20040053300A1 (en) * 2001-01-10 2004-03-18 Hans Soderlund Method and test kit for quantitative determination of variations in polynucleotide amounts in cell or tissue samples
US20040067501A1 (en) * 2000-10-03 2004-04-08 Andreas Kage Method of selection by two-dimensional separation, of nucleic acids that bind to a target with high affinity
US20040115696A1 (en) * 1996-12-06 2004-06-17 Nanotronics, Inc. Affinity based self-assembly systems and devices for photonic and electronic applications
US20040152100A1 (en) * 2001-05-31 2004-08-05 Katrin Zwiglmaier Method for sorting cells
US20040180369A1 (en) * 2003-01-16 2004-09-16 North Carolina State University Photothermal detection of nucleic acid hybridization
US20040241679A1 (en) * 2001-05-25 2004-12-02 Lee Marin Alan Detection system
US20050003366A1 (en) * 2001-02-20 2005-01-06 Getts Robert C. Method for reusing standard blots and microarrays utilizing DNA dendrimer technology
US20050053962A1 (en) * 1998-01-27 2005-03-10 Gary Blackburn Amplification of nucleic acids with electronic detection
US20050059030A1 (en) * 2002-12-12 2005-03-17 Nanosphere, Inc. Direct SNP detection with unamplified DNA
US20050112647A1 (en) * 1997-11-29 2005-05-26 The Secretary Of State For Defence Detection system
US20050164199A1 (en) * 2002-05-10 2005-07-28 Manfred Stanzel Method for biochemical analysis of dna and arrangement associated therewith
US20050186619A1 (en) * 1999-05-19 2005-08-25 Jonas Korlach Nucleic acid analysis using terminal-phosphate-labeled nucleotides
US20050191651A1 (en) * 2003-10-30 2005-09-01 North Carolina State University Temperature-jump enhanced electrochemical detection of nucleic acid hybridization
US20050221370A1 (en) * 2000-09-06 2005-10-06 Hodge Timothy A Systems and methods for ordering, performing, and reporting genetic screening
US20050260574A1 (en) * 2000-07-27 2005-11-24 Gibbs Mark J Combinatorial probes and uses therefor
US20050272085A1 (en) * 2000-09-06 2005-12-08 Hodge Timothy A Methods for forensic and congenic screening
US20060014186A1 (en) * 2001-09-04 2006-01-19 Hodge Timothy A Methods for genotype screening of a strain disposed on an adsorbent carrier
US20060035228A1 (en) * 2002-07-05 2006-02-16 Hans Soderlund Method and test kit for quantitative determination of polynucleotides in a mixture
US20060088838A1 (en) * 2002-06-12 2006-04-27 Murray Christopher J Methods for improving a binding characteristic of a molecule
US20060127906A1 (en) * 2002-10-10 2006-06-15 Lee Martin A Detection system
US20060211024A1 (en) * 2005-03-10 2006-09-21 Gwc Technologies Incorporated Methods for analysis of a nucleic acid sample
US20060228744A1 (en) * 2003-05-15 2006-10-12 Ghazala Hashmi Differentiating homozygous, heterozygous and wild-type alleles using a multiplexed hybridization-mediated assay
US20060246460A1 (en) * 2003-08-26 2006-11-02 University Of Strathclyde Nucleic acid sequence identification
US20060269916A1 (en) * 2002-11-22 2006-11-30 Dynal Biotech Inc. Probes
US20070003953A1 (en) * 2005-06-30 2007-01-04 Ge Healthcare Bio-Sciences Corp. Detection method for gene expression
US20070031870A1 (en) * 2005-07-25 2007-02-08 Roche Molecular Systems, Inc. Methods and reagents for detecting target nucleic acids
US20070065847A1 (en) * 2005-08-11 2007-03-22 Affymetrix, Inc. Degeneratively Labeled Probes
US20070072219A1 (en) * 2005-09-13 2007-03-29 Jose Remacle Detection method of homologous sequences differing by one base on a microarray
US20070077629A1 (en) * 2003-06-30 2007-04-05 Shigeki Joko Method for modifying nucleotide chain
US20070141604A1 (en) * 2005-11-15 2007-06-21 Gormley Niall A Method of target enrichment
US20070154888A1 (en) * 2003-05-22 2007-07-05 Holger Klapproth Method for the covalent immobilization of probe biomolecules on organic surfaces
US20070161028A1 (en) * 2005-11-29 2007-07-12 Schwartz David C Method of DNA analysis using micro/nanochannel
US20070166739A1 (en) * 2005-12-23 2007-07-19 Perkinelmer Las, Inc. Comparative genomic hybridization on encoded multiplex particles
US20070196832A1 (en) * 2006-02-22 2007-08-23 Efcavitch J William Methods for mutation detection
US20070196853A1 (en) * 2000-09-06 2007-08-23 Transnetyx, Inc. Methods For Rapid Genotype Screening
US20080004208A1 (en) * 2004-12-03 2008-01-03 Aichi Prefecture Methods for Diagnosis and Prognosis of Malignant Lymphoma
US20080044822A1 (en) * 2006-08-21 2008-02-21 Gafur Zainiev Nucleic acid array with releaseable nucleic acid probes
US20080044821A1 (en) * 2006-08-21 2008-02-21 Gafur Zainiev Nucleic acid array having fixed nucleic acid anti-probes and complementary free nucleic acid probes
US20080050724A1 (en) * 2006-08-24 2008-02-28 Microfluidic Systems, Inc. Method of detecting one or more limited copy targets
US20080096213A1 (en) * 2006-09-21 2008-04-24 Sysmex Corporation Method for confirming conversion treatment and nucleic acid molecule used therefor
US20080108711A1 (en) * 2004-10-25 2008-05-08 Felipe Voces-Sanchez Use of the Slug Gene or the Replication, Transcription or Expression Products Thereof in the Identification, Diagnosis, Prevention or Treatment of the Spread of Cancer and/or the Development of Metastasis
US20080138801A1 (en) * 2004-05-28 2008-06-12 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Surface Plasmon Resonance Sensor for Detecting Changes in Polynucleotide Mass
US20080145857A1 (en) * 2006-12-14 2008-06-19 Hisao Saito Microorganism detection system
US20080171325A1 (en) * 1997-04-17 2008-07-17 Cytonix Method and device for detecting the presence of a single target nucleic acid in a sample
US20080182235A1 (en) * 2007-01-30 2008-07-31 Celsis International Plc Detection of Analytes in Samples Using Liposome-Amplified Luminescence and Magnetic Separation
JP2008182920A (en) * 2007-01-29 2008-08-14 Sony Corp Fluorescence-labeled oligonucleotide and method for utilizing oligonucleotide
US20080220979A1 (en) * 2003-08-13 2008-09-11 Capitalbio Corporation Rapid Method To Detect Nucleic Acid Molecules
US20090104613A1 (en) * 2005-12-23 2009-04-23 Perkinelmer Las, Inc. Methods and compositions relating to multiplexed genomic gain and loss assays
US20090142755A1 (en) * 2007-11-29 2009-06-04 Maher Albitar Assay for detecting genetic abnormalities in genomic nucleic acids
US20090148841A1 (en) * 2007-12-05 2009-06-11 Perkinelmer Las, Inc. Multiplexed genomic gain and loss assays
US20090286694A1 (en) * 2006-08-21 2009-11-19 Gafur Zainiev Nucleic acid array with releaseable nucleic acid probes
US20100000881A1 (en) * 2003-10-30 2010-01-07 North Carolina State University Electrochemical detection of nucleic acid hybridization
US20100009373A1 (en) * 2005-12-23 2010-01-14 Perkinelmer Health Sciences, Inc. Methods and compositions relating to multiplex genomic gain and loss assays
US20100056388A1 (en) * 2006-08-21 2010-03-04 Cnvgenes, Inc. Nucleic acid array having fixed nucleic acid anti-probes and complementary free nucleic acid probes
US20100093550A1 (en) * 2006-10-10 2010-04-15 Stuelpnagel John R Compositions and methods for representational selection of nucleic acids from complex mixtures using hybridization
US20100291637A1 (en) * 2003-06-30 2010-11-18 Panasonic Corporation Method for modifying nucleotide chain
US20150045249A1 (en) * 2012-02-27 2015-02-12 Toray Industries, Inc. Nucleic acid detection method
US20150126400A1 (en) * 2012-02-10 2015-05-07 Raindance Technologies, Inc. Molecular diagnostic screening assay
US20150197790A1 (en) * 2014-01-10 2015-07-16 Bio-Rad Laboratories, Inc. Intercalating dyes for differential detection
US20150368712A1 (en) * 2008-07-30 2015-12-24 Nippon Steel & Sumikin Eco-Tech Corporation Universal nucleic acid probe set and method for utilization thereof
US20160273027A1 (en) * 2013-11-26 2016-09-22 Bio-Rad Laboratories, Inc. Methods for detecting nucleic acids proximity
US20160299129A1 (en) * 2015-04-07 2016-10-13 Xiaolei Qiu Ultra Sensitive and Specific Multiplex Biosensor System Based on Multiple Cooperative Interactions
US20170145476A1 (en) * 2015-11-19 2017-05-25 10X Genomics, Inc. Transformable tagging compositions, methods, and processes incorporating same
US20170152552A1 (en) * 2015-11-30 2017-06-01 Sysmex Corporation Cell selection method, cell detection method, cell selection apparatus, and cell detection apparatus
US20170342471A1 (en) * 2014-12-19 2017-11-30 Eiken Kagaku Kabushiki Kaisha Oligonucleotide Probe for Detecting Single Nucleotide Polymorphism, and Method for Detecting Single Nucleotide Polymorphism
US20180057867A1 (en) * 2013-03-14 2018-03-01 President And Fellows Of Harvard College Methods of Hybridizing Probes to Genomic DNA
US20180237832A1 (en) * 2011-09-29 2018-08-23 Luminex Corporation Hydrolysis probes
US20180327818A1 (en) * 2014-08-01 2018-11-15 Olink Bioscience Ab Method for selecting a target nucleic acid sequence
US10669583B2 (en) 2012-08-14 2020-06-02 10X Genomics, Inc. Method and systems for processing polynucleotides
US10676789B2 (en) 2012-12-14 2020-06-09 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10683551B2 (en) 2011-02-15 2020-06-16 Bio-Rad Laboratories, Inc. Detecting methylation in a subpopulation of genomic DNA
US10745742B2 (en) 2017-11-15 2020-08-18 10X Genomics, Inc. Functionalized gel beads
US10752949B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10752950B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10760126B2 (en) 2010-09-10 2020-09-01 Bio-Rad Laboratories, Inc. Detection of RNA-interacting regions in DNA
US10829815B2 (en) 2017-11-17 2020-11-10 10X Genomics, Inc. Methods and systems for associating physical and genetic properties of biological particles
US11168353B2 (en) 2011-02-18 2021-11-09 Bio-Rad Laboratories, Inc. Compositions and methods for molecular labeling
US11174509B2 (en) 2013-12-12 2021-11-16 Bio-Rad Laboratories, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
US11187702B2 (en) 2003-03-14 2021-11-30 Bio-Rad Laboratories, Inc. Enzyme quantification
US11193121B2 (en) 2013-02-08 2021-12-07 10X Genomics, Inc. Partitioning and processing of analytes and other species
US11224876B2 (en) 2007-04-19 2022-01-18 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
US11254968B2 (en) 2010-02-12 2022-02-22 Bio-Rad Laboratories, Inc. Digital analyte analysis
US11274343B2 (en) 2015-02-24 2022-03-15 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequence coverage
US11287422B2 (en) 2019-09-23 2022-03-29 Element Biosciences, Inc. Multivalent binding composition for nucleic acid analysis
US11351510B2 (en) 2006-05-11 2022-06-07 Bio-Rad Laboratories, Inc. Microfluidic devices
US11371094B2 (en) 2015-11-19 2022-06-28 10X Genomics, Inc. Systems and methods for nucleic acid processing using degenerate nucleotides
US11390917B2 (en) 2010-02-12 2022-07-19 Bio-Rad Laboratories, Inc. Digital analyte analysis
US11414688B2 (en) 2015-01-12 2022-08-16 10X Genomics, Inc. Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same
US11473138B2 (en) 2012-12-14 2022-10-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11511242B2 (en) 2008-07-18 2022-11-29 Bio-Rad Laboratories, Inc. Droplet libraries
US11591637B2 (en) 2012-08-14 2023-02-28 10X Genomics, Inc. Compositions and methods for sample processing
US11629344B2 (en) 2014-06-26 2023-04-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11819849B2 (en) 2007-02-06 2023-11-21 Brandeis University Manipulation of fluids and reactions in microfluidic systems
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US11898193B2 (en) 2011-07-20 2024-02-13 Bio-Rad Laboratories, Inc. Manipulating droplet size

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002064833A1 (en) * 2001-02-15 2002-08-22 Takara Bio Inc. Method of detecting nucleotide polymorphism
EP1456409B1 (en) * 2001-11-28 2010-02-24 Bio-Rad Laboratories, Inc. Parallel polymorphism scoring by amplification and error correction
WO2005098042A2 (en) * 2004-04-01 2005-10-20 Bio-Rad Laboratories, Inc. Quantitative amplification with a labeled probe and 3' to 5' exonuclease activity
US20080050735A1 (en) * 2006-02-01 2008-02-28 Elena Pushnova Nucleic acid testing method for point-of-care diagnostics and genetic self-monitoring
JP2012502660A (en) * 2008-09-22 2012-02-02 エフ.ホフマン−ラ ロシュ アーゲー Selective processing of biological materials on microarray substrates
JP5818688B2 (en) 2009-01-08 2015-11-18 バイオ−ラッド ラボラトリーズ インコーポレーティッド Methods and compositions for improving the efficiency of nucleic acid amplification reactions
US9617588B2 (en) 2010-10-05 2017-04-11 Thermo Fisher Scientific Baltics Uab Enzyme mixture
SG193990A1 (en) 2011-04-08 2013-11-29 Bio Rad Laboratories Pcr reaction mixtures with decreased non-specific activity
JP6404118B2 (en) * 2011-05-04 2018-10-10 バイオセプト インコーポレイティッド Method for detecting nucleic acid sequence variants
EP3486329A1 (en) 2015-02-17 2019-05-22 Bio-Rad Laboratories, Inc. Method of generating and amplifying cdna
CN107760704A (en) * 2016-08-23 2018-03-06 南京理工大学 Based on recombinant vector pGPE57 recombinant bacterial strain E.coli GPE10 and its construction method and application
CN111044498B (en) * 2019-12-26 2021-05-18 华中科技大学 Fluorescent probe identification method, and multicolor super-resolution positioning imaging method and system

Citations (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851331A (en) * 1986-05-16 1989-07-25 Allied Corporation Method and kit for polynucleotide assay including primer-dependant DNA polymerase
US5210015A (en) * 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US5391480A (en) * 1989-03-21 1995-02-21 Collaborative Research, Inc. Method for detecting a nucleotide at a specific location within a nucleic acid using exonuclease activity
US5521301A (en) * 1988-12-12 1996-05-28 City Of Hope Genotyping of multiple allele systems
US5545552A (en) * 1990-12-03 1996-08-13 Stratagene Purified thermostable pyrococcus furiosus DNA polymerase I
US5639611A (en) * 1988-12-12 1997-06-17 City Of Hope Allele specific polymerase chain reaction
US5736626A (en) * 1996-01-29 1998-04-07 The Perkin-Elmer Corporation Solid support reagents for the direct synthesis of 3'-labeled polynucleotides
US5759772A (en) * 1992-07-23 1998-06-02 Wisconsin Alumni Research Foundation Method for determining the sex of an embryo
US5848717A (en) * 1995-05-01 1998-12-15 Crown Cork Ag Snap-on seal arrangement on a container
US5851770A (en) * 1994-04-25 1998-12-22 Variagenics, Inc. Detection of mismatches by resolvase cleavage using a magnetic bead support
US5955268A (en) * 1996-04-26 1999-09-21 Abbott Laboratories Method and reagent for detecting multiple nucleic acid sequences in a test sample
US6001567A (en) * 1996-01-24 1999-12-14 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
US6120992A (en) * 1993-11-04 2000-09-19 Valigene Corporation Use of immobilized mismatch binding protein for detection of mutations and polymorphisms, and allele identification in a diseased human
US6174670B1 (en) * 1996-06-04 2001-01-16 University Of Utah Research Foundation Monitoring amplification of DNA during PCR
US6248526B1 (en) * 1997-12-15 2001-06-19 Aventis Behring, Gmbh Labeled primer for use in and detection of target nucleic acids
US20020053279A1 (en) * 2000-07-11 2002-05-09 Jung Tae Suk Bulletproof equipment
US20020142336A1 (en) * 2001-02-02 2002-10-03 Genome Therapeutics Corporation Methods for determining a nucleotide at a specific location within a nucleic acid molecule
US20030036073A1 (en) * 2001-06-07 2003-02-20 Saba James Anthony Matrix Sequencing: a novel method of polynucleotide analysis utilizing probes containing universal nucleotides
US6627424B1 (en) * 2000-05-26 2003-09-30 Mj Bioworks, Inc. Nucleic acid modifying enzymes
US20030219765A1 (en) * 2000-03-23 2003-11-27 Jose Costa Methods for evaluating cancer risk
US7163790B2 (en) * 2001-11-28 2007-01-16 Bio-Rad Laboratories, Inc. Parallel polymorphism scoring by amplification and error correction

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1190838A (en) 1981-07-17 1985-07-23 Cavit Akin Homogeneous nucleic acid hybridization diagnostics by non-radiative energy transfer
US5972603A (en) * 1996-02-09 1999-10-26 President And Fellows Of Harvard College DNA polymerase with modified processivity
ATE395420T1 (en) 2000-02-17 2008-05-15 Qiagen Gmbh THERMOSTABLE CHIMERIC NUCLEIC ACID POLYMERASES AND USES THEREOF
DE10049211A1 (en) * 2000-10-05 2002-04-18 Qiagen Gmbh Thermostable polymerase from Thermococcus pacificus
US7560260B2 (en) * 2002-07-25 2009-07-14 Bio-Rad Laboratories, Inc. Compositions with polymerase activity

Patent Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851331A (en) * 1986-05-16 1989-07-25 Allied Corporation Method and kit for polynucleotide assay including primer-dependant DNA polymerase
US5521301A (en) * 1988-12-12 1996-05-28 City Of Hope Genotyping of multiple allele systems
US5639611A (en) * 1988-12-12 1997-06-17 City Of Hope Allele specific polymerase chain reaction
US5391480A (en) * 1989-03-21 1995-02-21 Collaborative Research, Inc. Method for detecting a nucleotide at a specific location within a nucleic acid using exonuclease activity
US5210015A (en) * 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US5487972A (en) * 1990-08-06 1996-01-30 Hoffmann-La Roche Inc. Nucleic acid detection by the 5'-3'exonuclease activity of polymerases acting on adjacently hybridized oligonucleotides
US5545552A (en) * 1990-12-03 1996-08-13 Stratagene Purified thermostable pyrococcus furiosus DNA polymerase I
US5759772A (en) * 1992-07-23 1998-06-02 Wisconsin Alumni Research Foundation Method for determining the sex of an embryo
US6120992A (en) * 1993-11-04 2000-09-19 Valigene Corporation Use of immobilized mismatch binding protein for detection of mutations and polymorphisms, and allele identification in a diseased human
US5851770A (en) * 1994-04-25 1998-12-22 Variagenics, Inc. Detection of mismatches by resolvase cleavage using a magnetic bead support
US5848717A (en) * 1995-05-01 1998-12-15 Crown Cork Ag Snap-on seal arrangement on a container
US6001567A (en) * 1996-01-24 1999-12-14 Third Wave Technologies, Inc. Detection of nucleic acid sequences by invader-directed cleavage
US5736626A (en) * 1996-01-29 1998-04-07 The Perkin-Elmer Corporation Solid support reagents for the direct synthesis of 3'-labeled polynucleotides
US5955268A (en) * 1996-04-26 1999-09-21 Abbott Laboratories Method and reagent for detecting multiple nucleic acid sequences in a test sample
US6174670B1 (en) * 1996-06-04 2001-01-16 University Of Utah Research Foundation Monitoring amplification of DNA during PCR
US6248526B1 (en) * 1997-12-15 2001-06-19 Aventis Behring, Gmbh Labeled primer for use in and detection of target nucleic acids
US20030219765A1 (en) * 2000-03-23 2003-11-27 Jose Costa Methods for evaluating cancer risk
US6627424B1 (en) * 2000-05-26 2003-09-30 Mj Bioworks, Inc. Nucleic acid modifying enzymes
US20020053279A1 (en) * 2000-07-11 2002-05-09 Jung Tae Suk Bulletproof equipment
US20020142336A1 (en) * 2001-02-02 2002-10-03 Genome Therapeutics Corporation Methods for determining a nucleotide at a specific location within a nucleic acid molecule
US20030036073A1 (en) * 2001-06-07 2003-02-20 Saba James Anthony Matrix Sequencing: a novel method of polynucleotide analysis utilizing probes containing universal nucleotides
US7163790B2 (en) * 2001-11-28 2007-01-16 Bio-Rad Laboratories, Inc. Parallel polymorphism scoring by amplification and error correction

Cited By (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040115696A1 (en) * 1996-12-06 2004-06-17 Nanotronics, Inc. Affinity based self-assembly systems and devices for photonic and electronic applications
US20120301884A1 (en) * 1997-04-17 2012-11-29 United States Department of Health and Human Services Method and device for detecting the presence of a single target nucleic acid in a sample
US9506105B2 (en) 1997-04-17 2016-11-29 Applied Biosystems, Llc Device and method for amplifying target nucleic acid
US8822183B2 (en) 1997-04-17 2014-09-02 Applied Biosystems, Llc Device for amplifying target nucleic acid
US20080171325A1 (en) * 1997-04-17 2008-07-17 Cytonix Method and device for detecting the presence of a single target nucleic acid in a sample
US8563275B2 (en) * 1997-04-17 2013-10-22 Applied Biosystems, Llc Method and device for detecting the presence of a single target nucleic acid in a sample
US20050112647A1 (en) * 1997-11-29 2005-05-26 The Secretary Of State For Defence Detection system
US20020177144A1 (en) * 1997-12-30 2002-11-28 Jose Remacle Detection and/or quantification method of a target molecule by a binding with a capture molecule fixed on the surface of a disc
US20050053962A1 (en) * 1998-01-27 2005-03-10 Gary Blackburn Amplification of nucleic acids with electronic detection
US20080227654A1 (en) * 1999-05-19 2008-09-18 Jonas Korlach Method for sequencing nucleic acid molecules
US20060211010A1 (en) * 1999-05-19 2006-09-21 Jonas Korlach Labeled nucleotide phosphate (NP) probes
US20060134666A1 (en) * 1999-05-19 2006-06-22 Jonas Korlach Methods for detecting nucleic acid analyte
US20060057606A1 (en) * 1999-05-19 2006-03-16 Jonas Korlach Reagents containing terminal-phosphate-labeled nucleotides for nucleic acid sequencing
US7485424B2 (en) * 1999-05-19 2009-02-03 Cornell Research Foundation, Inc. Labeled nucleotide phosphate (NP) probes
US7361466B2 (en) 1999-05-19 2008-04-22 Cornell Research Foundation, Inc. Nucleic acid analysis using terminal-phosphate-labeled nucleotides
US7943305B2 (en) 1999-05-19 2011-05-17 Cornell Research Foundation High speed nucleic acid sequencing
US20070026447A1 (en) * 1999-05-19 2007-02-01 Jonas Korlach Nucleotides
US20030096321A1 (en) * 1999-05-19 2003-05-22 Jose Remacle Method for the identification and/or the quantification of a target compound obtained from a biological sample upon chips
US7416844B2 (en) 1999-05-19 2008-08-26 Cornell Research Foundation, Inc. Composition for nucleic acid sequencing
US20100113301A1 (en) * 1999-05-19 2010-05-06 Eppendorf Array Technologies Method for the identification and/or the quantification of a target compound obtained from a biological sample upon chips
US20060188900A1 (en) * 1999-05-19 2006-08-24 Jonas Korlach High speed nucleic acid sequencing
US20050186619A1 (en) * 1999-05-19 2005-08-25 Jonas Korlach Nucleic acid analysis using terminal-phosphate-labeled nucleotides
US20060160113A1 (en) * 1999-05-19 2006-07-20 Jonas Korlach Terminal-phosphate-labeled nucleotides
US20050208557A1 (en) * 1999-05-19 2005-09-22 Jonas Korlach Uses of terminal-phosphate-labeled nucleotides
US20110111401A1 (en) * 1999-05-19 2011-05-12 Cornell University Method for sequencing nucleic acid molecules
US20030215891A1 (en) * 2000-07-01 2003-11-20 Ralf Bickel Method for the qualitative and/or quantitative detection of molecular interactions on probe arrays
US20050260574A1 (en) * 2000-07-27 2005-11-24 Gibbs Mark J Combinatorial probes and uses therefor
US20050221370A1 (en) * 2000-09-06 2005-10-06 Hodge Timothy A Systems and methods for ordering, performing, and reporting genetic screening
US20080027217A1 (en) * 2000-09-06 2008-01-31 Transnetyx, Inc. Method to Obtain Purified Human Genomic Nucleic Acid
US20050272085A1 (en) * 2000-09-06 2005-12-08 Hodge Timothy A Methods for forensic and congenic screening
US20070196853A1 (en) * 2000-09-06 2007-08-23 Transnetyx, Inc. Methods For Rapid Genotype Screening
US20040067501A1 (en) * 2000-10-03 2004-04-08 Andreas Kage Method of selection by two-dimensional separation, of nucleic acids that bind to a target with high affinity
US20090029363A1 (en) * 2000-10-03 2009-01-29 Aptares Ag Method of selection by two-dimensional separation, of nucleic acids that bind to a target with high affinity
US20020142326A1 (en) * 2000-11-30 2002-10-03 Coull James M. Methods and compositions for sorting and/or determining organisms
US9416401B2 (en) * 2001-01-10 2016-08-16 Valtion Teknillinen Tutkimuskeskus Method for determining amounts of polynucleotide sequences present in cell or tissue samples
US20040053300A1 (en) * 2001-01-10 2004-03-18 Hans Soderlund Method and test kit for quantitative determination of variations in polynucleotide amounts in cell or tissue samples
US7504239B2 (en) * 2001-02-09 2009-03-17 Sapporo Breweries Limited Method of differentiating beer yeast
US20030104405A1 (en) * 2001-02-09 2003-06-05 Sapporo Breweries Limited Method of differentiating beer yeast
US20050003366A1 (en) * 2001-02-20 2005-01-06 Getts Robert C. Method for reusing standard blots and microarrays utilizing DNA dendrimer technology
US7700275B2 (en) 2001-05-25 2010-04-20 The Secretary Of State Of Defense Detection system
US20040241679A1 (en) * 2001-05-25 2004-12-02 Lee Marin Alan Detection system
US20100227326A1 (en) * 2001-05-25 2010-09-09 The Secretary Of State For Defence Detection System
US20040152100A1 (en) * 2001-05-31 2004-08-05 Katrin Zwiglmaier Method for sorting cells
US20030143581A1 (en) * 2001-07-20 2003-07-31 Stefan Franzen Light addressable electrochemical detection of duplex structures
US7829275B2 (en) 2001-07-20 2010-11-09 North Carolina State University Light addressable electrochemical detection of duplex structures
US20060014186A1 (en) * 2001-09-04 2006-01-19 Hodge Timothy A Methods for genotype screening of a strain disposed on an adsorbent carrier
US20030207289A1 (en) * 2001-09-04 2003-11-06 Hodge Timothy A. Detection of genetic sequences using a bipartite probe
US20030059822A1 (en) * 2001-09-18 2003-03-27 U.S. Genomics, Inc. Differential tagging of polymers for high resolution linear analysis
US20050164199A1 (en) * 2002-05-10 2005-07-28 Manfred Stanzel Method for biochemical analysis of dna and arrangement associated therewith
US20040029160A1 (en) * 2002-05-24 2004-02-12 Ramon Eritja Parallel stranded duplexes of deoxyribonucleic acid and methods of use
US7371520B2 (en) 2002-05-28 2008-05-13 U.S. Genomics, Inc. Methods and apparati using single polymer analysis
US20040009612A1 (en) * 2002-05-28 2004-01-15 Xiaojian Zhao Methods and apparati using single polymer analysis
US20060088838A1 (en) * 2002-06-12 2006-04-27 Murray Christopher J Methods for improving a binding characteristic of a molecule
US20080146456A1 (en) * 2002-06-12 2008-06-19 Murray Christopher J Methods For Improving a Binding Characteristic of a Molecule
US20080233591A1 (en) * 2002-07-05 2008-09-25 Valtion Teknillinen Tutkimuskeskus Method and test kit for quantitative determination of polynucleotides in a mixture
US20060035228A1 (en) * 2002-07-05 2006-02-16 Hans Soderlund Method and test kit for quantitative determination of polynucleotides in a mixture
US7361461B2 (en) 2002-07-05 2008-04-22 Valtion Teknillinen Tutkimuskeskus Method and test kit for quantitative determination of polynucleotides in a mixture
US8143388B2 (en) 2002-07-05 2012-03-27 Valtion Teknillinen Tutkimuskeskus Method and test kit for quantitative determination of polynucleotides in a mixture
US20060127906A1 (en) * 2002-10-10 2006-06-15 Lee Martin A Detection system
US20060269916A1 (en) * 2002-11-22 2006-11-30 Dynal Biotech Inc. Probes
US20050059030A1 (en) * 2002-12-12 2005-03-17 Nanosphere, Inc. Direct SNP detection with unamplified DNA
US20040180369A1 (en) * 2003-01-16 2004-09-16 North Carolina State University Photothermal detection of nucleic acid hybridization
US11187702B2 (en) 2003-03-14 2021-11-30 Bio-Rad Laboratories, Inc. Enzyme quantification
US7501266B2 (en) * 2003-05-15 2009-03-10 Bioarray Solutions, Ltd. Differentiating homozygous, heterozygous and wild-type alleles using a multiplexed hybridization-mediated assay
US7771939B2 (en) * 2003-05-15 2010-08-10 Bioarray Solutions, Ltd. Correcting an assay image of an array of signals generated from a multiplexed hybridization-mediated assay
US20060228742A1 (en) * 2003-05-15 2006-10-12 Ghazala Hashmi Correcting an assay image of an array of signals generated from a multiplexed hybridization-mediated assay
US20060228744A1 (en) * 2003-05-15 2006-10-12 Ghazala Hashmi Differentiating homozygous, heterozygous and wild-type alleles using a multiplexed hybridization-mediated assay
US20070154888A1 (en) * 2003-05-22 2007-07-05 Holger Klapproth Method for the covalent immobilization of probe biomolecules on organic surfaces
US20100291637A1 (en) * 2003-06-30 2010-11-18 Panasonic Corporation Method for modifying nucleotide chain
US20070077629A1 (en) * 2003-06-30 2007-04-05 Shigeki Joko Method for modifying nucleotide chain
US20080220979A1 (en) * 2003-08-13 2008-09-11 Capitalbio Corporation Rapid Method To Detect Nucleic Acid Molecules
US20060246460A1 (en) * 2003-08-26 2006-11-02 University Of Strathclyde Nucleic acid sequence identification
US20050191651A1 (en) * 2003-10-30 2005-09-01 North Carolina State University Temperature-jump enhanced electrochemical detection of nucleic acid hybridization
US20100000881A1 (en) * 2003-10-30 2010-01-07 North Carolina State University Electrochemical detection of nucleic acid hybridization
US20080138801A1 (en) * 2004-05-28 2008-06-12 Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Surface Plasmon Resonance Sensor for Detecting Changes in Polynucleotide Mass
US20080108711A1 (en) * 2004-10-25 2008-05-08 Felipe Voces-Sanchez Use of the Slug Gene or the Replication, Transcription or Expression Products Thereof in the Identification, Diagnosis, Prevention or Treatment of the Spread of Cancer and/or the Development of Metastasis
US7790382B2 (en) * 2004-10-25 2010-09-07 Oncostem Pharma, S.L. Use of the transcription of the slug gene in evaluating the redisposition of a subject with cancer to develop metastatis
US20080004208A1 (en) * 2004-12-03 2008-01-03 Aichi Prefecture Methods for Diagnosis and Prognosis of Malignant Lymphoma
US20060211024A1 (en) * 2005-03-10 2006-09-21 Gwc Technologies Incorporated Methods for analysis of a nucleic acid sample
US7914983B2 (en) * 2005-06-30 2011-03-29 Ge Healthcare Bio-Sciences Corp. Detection method for gene expression
US20070003953A1 (en) * 2005-06-30 2007-01-04 Ge Healthcare Bio-Sciences Corp. Detection method for gene expression
US20070031870A1 (en) * 2005-07-25 2007-02-08 Roche Molecular Systems, Inc. Methods and reagents for detecting target nucleic acids
US7977108B2 (en) * 2005-07-25 2011-07-12 Roche Molecular Systems, Inc. Method for detecting a mutation in a repetitive nucleic acid sequence
US20070065847A1 (en) * 2005-08-11 2007-03-22 Affymetrix, Inc. Degeneratively Labeled Probes
US20070072219A1 (en) * 2005-09-13 2007-03-29 Jose Remacle Detection method of homologous sequences differing by one base on a microarray
US20070141604A1 (en) * 2005-11-15 2007-06-21 Gormley Niall A Method of target enrichment
US7960105B2 (en) * 2005-11-29 2011-06-14 National Institutes Of Health Method of DNA analysis using micro/nanochannel
US20070161028A1 (en) * 2005-11-29 2007-07-12 Schwartz David C Method of DNA analysis using micro/nanochannel
US20100009373A1 (en) * 2005-12-23 2010-01-14 Perkinelmer Health Sciences, Inc. Methods and compositions relating to multiplex genomic gain and loss assays
US20090104613A1 (en) * 2005-12-23 2009-04-23 Perkinelmer Las, Inc. Methods and compositions relating to multiplexed genomic gain and loss assays
US20070166739A1 (en) * 2005-12-23 2007-07-19 Perkinelmer Las, Inc. Comparative genomic hybridization on encoded multiplex particles
US20070196832A1 (en) * 2006-02-22 2007-08-23 Efcavitch J William Methods for mutation detection
US11351510B2 (en) 2006-05-11 2022-06-07 Bio-Rad Laboratories, Inc. Microfluidic devices
US20100056388A1 (en) * 2006-08-21 2010-03-04 Cnvgenes, Inc. Nucleic acid array having fixed nucleic acid anti-probes and complementary free nucleic acid probes
US20080044821A1 (en) * 2006-08-21 2008-02-21 Gafur Zainiev Nucleic acid array having fixed nucleic acid anti-probes and complementary free nucleic acid probes
US20090286694A1 (en) * 2006-08-21 2009-11-19 Gafur Zainiev Nucleic acid array with releaseable nucleic acid probes
US20080044822A1 (en) * 2006-08-21 2008-02-21 Gafur Zainiev Nucleic acid array with releaseable nucleic acid probes
US20080050724A1 (en) * 2006-08-24 2008-02-28 Microfluidic Systems, Inc. Method of detecting one or more limited copy targets
US20080096213A1 (en) * 2006-09-21 2008-04-24 Sysmex Corporation Method for confirming conversion treatment and nucleic acid molecule used therefor
US8568979B2 (en) 2006-10-10 2013-10-29 Illumina, Inc. Compositions and methods for representational selection of nucleic acids from complex mixtures using hybridization
US9587273B2 (en) 2006-10-10 2017-03-07 Illumina, Inc. Compositions and methods for representational selection of nucleic acids from complex mixtures using hybridization
US10538759B2 (en) 2006-10-10 2020-01-21 Illumina, Inc. Compounds and method for representational selection of nucleic acids from complex mixtures using hybridization
US9340781B2 (en) 2006-10-10 2016-05-17 Illumina, Inc. Compositions and methods for representational selection of nucleic acids from complex mixtures using hybridization
US9139826B2 (en) 2006-10-10 2015-09-22 Illumina, Inc. Compositions and methods for representational selection of nucleic acids from complex mixtures using hybridization
US20100093550A1 (en) * 2006-10-10 2010-04-15 Stuelpnagel John R Compositions and methods for representational selection of nucleic acids from complex mixtures using hybridization
US8916350B2 (en) 2006-10-10 2014-12-23 Illumina, Inc. Compositions and methods for representational selection of nucleic acids from complex mixtures using hybridization
US20080145857A1 (en) * 2006-12-14 2008-06-19 Hisao Saito Microorganism detection system
JP2008182920A (en) * 2007-01-29 2008-08-14 Sony Corp Fluorescence-labeled oligonucleotide and method for utilizing oligonucleotide
US20080182235A1 (en) * 2007-01-30 2008-07-31 Celsis International Plc Detection of Analytes in Samples Using Liposome-Amplified Luminescence and Magnetic Separation
US11819849B2 (en) 2007-02-06 2023-11-21 Brandeis University Manipulation of fluids and reactions in microfluidic systems
US11618024B2 (en) 2007-04-19 2023-04-04 President And Fellows Of Harvard College Manipulation of fluids, fluid components and reactions in microfluidic systems
US11224876B2 (en) 2007-04-19 2022-01-18 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
US8093063B2 (en) * 2007-11-29 2012-01-10 Quest Diagnostics Investments Incorporated Assay for detecting genetic abnormalities in genomic nucleic acids
US20090142755A1 (en) * 2007-11-29 2009-06-04 Maher Albitar Assay for detecting genetic abnormalities in genomic nucleic acids
US8404463B2 (en) 2007-12-05 2013-03-26 Perkinelmer Health Sciences, Inc. DNA assays using amplicon probes on encoded particles
US7932037B2 (en) 2007-12-05 2011-04-26 Perkinelmer Health Sciences, Inc. DNA assays using amplicon probes on encoded particles
US20110172117A1 (en) * 2007-12-05 2011-07-14 Perkinelmer Health Sciences, Inc. Multiplexed genomic gain and loss assays
US9127307B2 (en) 2007-12-05 2015-09-08 Perkinelmer Health Sciences, Inc. Reagents and methods relating to DNA assays using amplicon probes on encoded particles
US20090148841A1 (en) * 2007-12-05 2009-06-11 Perkinelmer Las, Inc. Multiplexed genomic gain and loss assays
US11534727B2 (en) 2008-07-18 2022-12-27 Bio-Rad Laboratories, Inc. Droplet libraries
US11511242B2 (en) 2008-07-18 2022-11-29 Bio-Rad Laboratories, Inc. Droplet libraries
US11596908B2 (en) 2008-07-18 2023-03-07 Bio-Rad Laboratories, Inc. Droplet libraries
US20150368712A1 (en) * 2008-07-30 2015-12-24 Nippon Steel & Sumikin Eco-Tech Corporation Universal nucleic acid probe set and method for utilization thereof
US11254968B2 (en) 2010-02-12 2022-02-22 Bio-Rad Laboratories, Inc. Digital analyte analysis
US11390917B2 (en) 2010-02-12 2022-07-19 Bio-Rad Laboratories, Inc. Digital analyte analysis
US10760126B2 (en) 2010-09-10 2020-09-01 Bio-Rad Laboratories, Inc. Detection of RNA-interacting regions in DNA
US10683551B2 (en) 2011-02-15 2020-06-16 Bio-Rad Laboratories, Inc. Detecting methylation in a subpopulation of genomic DNA
US11768198B2 (en) 2011-02-18 2023-09-26 Bio-Rad Laboratories, Inc. Compositions and methods for molecular labeling
US11747327B2 (en) 2011-02-18 2023-09-05 Bio-Rad Laboratories, Inc. Compositions and methods for molecular labeling
US11168353B2 (en) 2011-02-18 2021-11-09 Bio-Rad Laboratories, Inc. Compositions and methods for molecular labeling
US11754499B2 (en) 2011-06-02 2023-09-12 Bio-Rad Laboratories, Inc. Enzyme quantification
US11898193B2 (en) 2011-07-20 2024-02-13 Bio-Rad Laboratories, Inc. Manipulating droplet size
US20180237832A1 (en) * 2011-09-29 2018-08-23 Luminex Corporation Hydrolysis probes
US20150126400A1 (en) * 2012-02-10 2015-05-07 Raindance Technologies, Inc. Molecular diagnostic screening assay
US20150045249A1 (en) * 2012-02-27 2015-02-12 Toray Industries, Inc. Nucleic acid detection method
US10752950B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11035002B2 (en) 2012-08-14 2021-06-15 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11021749B2 (en) 2012-08-14 2021-06-01 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11441179B2 (en) 2012-08-14 2022-09-13 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10669583B2 (en) 2012-08-14 2020-06-02 10X Genomics, Inc. Method and systems for processing polynucleotides
US11591637B2 (en) 2012-08-14 2023-02-28 10X Genomics, Inc. Compositions and methods for sample processing
US10752949B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11359239B2 (en) 2012-08-14 2022-06-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11473138B2 (en) 2012-12-14 2022-10-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11421274B2 (en) 2012-12-14 2022-08-23 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10676789B2 (en) 2012-12-14 2020-06-09 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11193121B2 (en) 2013-02-08 2021-12-07 10X Genomics, Inc. Partitioning and processing of analytes and other species
US20180057867A1 (en) * 2013-03-14 2018-03-01 President And Fellows Of Harvard College Methods of Hybridizing Probes to Genomic DNA
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US20160273027A1 (en) * 2013-11-26 2016-09-22 Bio-Rad Laboratories, Inc. Methods for detecting nucleic acids proximity
US11174509B2 (en) 2013-12-12 2021-11-16 Bio-Rad Laboratories, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
US20150197790A1 (en) * 2014-01-10 2015-07-16 Bio-Rad Laboratories, Inc. Intercalating dyes for differential detection
US11629344B2 (en) 2014-06-26 2023-04-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11713457B2 (en) 2014-06-26 2023-08-01 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11352658B2 (en) * 2014-08-01 2022-06-07 Navinci Diagnostics Ab Method for selecting a target nucleic acid sequence
US20180327818A1 (en) * 2014-08-01 2018-11-15 Olink Bioscience Ab Method for selecting a target nucleic acid sequence
US20170342471A1 (en) * 2014-12-19 2017-11-30 Eiken Kagaku Kabushiki Kaisha Oligonucleotide Probe for Detecting Single Nucleotide Polymorphism, and Method for Detecting Single Nucleotide Polymorphism
US11512343B2 (en) * 2014-12-19 2022-11-29 Eiken Kagaku Kabushiki Kaisha Oligonucleotide probe for detecting single nucleotide polymorphism, and method for detecting single nucleotide polymorphism
US11414688B2 (en) 2015-01-12 2022-08-16 10X Genomics, Inc. Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same
US11274343B2 (en) 2015-02-24 2022-03-15 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequence coverage
US20160299129A1 (en) * 2015-04-07 2016-10-13 Xiaolei Qiu Ultra Sensitive and Specific Multiplex Biosensor System Based on Multiple Cooperative Interactions
US11371094B2 (en) 2015-11-19 2022-06-28 10X Genomics, Inc. Systems and methods for nucleic acid processing using degenerate nucleotides
US20170145476A1 (en) * 2015-11-19 2017-05-25 10X Genomics, Inc. Transformable tagging compositions, methods, and processes incorporating same
US11060134B2 (en) * 2015-11-30 2021-07-13 Sysmex Corporation Cell selection method, cell detection method, cell selection apparatus, and cell detection apparatus
US20170152552A1 (en) * 2015-11-30 2017-06-01 Sysmex Corporation Cell selection method, cell detection method, cell selection apparatus, and cell detection apparatus
US10745742B2 (en) 2017-11-15 2020-08-18 10X Genomics, Inc. Functionalized gel beads
US11884962B2 (en) 2017-11-15 2024-01-30 10X Genomics, Inc. Functionalized gel beads
US10876147B2 (en) 2017-11-15 2020-12-29 10X Genomics, Inc. Functionalized gel beads
US10829815B2 (en) 2017-11-17 2020-11-10 10X Genomics, Inc. Methods and systems for associating physical and genetic properties of biological particles
US11287422B2 (en) 2019-09-23 2022-03-29 Element Biosciences, Inc. Multivalent binding composition for nucleic acid analysis

Also Published As

Publication number Publication date
AU2002351193A1 (en) 2003-06-10
US7163790B2 (en) 2007-01-16
WO2003046208A3 (en) 2003-07-10
WO2003046208A2 (en) 2003-06-05
ATE458832T1 (en) 2010-03-15
US20030138830A1 (en) 2003-07-24
AU2002351193A8 (en) 2003-06-10
EP1456409A4 (en) 2005-08-10
EP1456409B1 (en) 2010-02-24
EP1456409A2 (en) 2004-09-15
DE60235491D1 (en) 2010-04-08

Similar Documents

Publication Publication Date Title
US7163790B2 (en) Parallel polymorphism scoring by amplification and error correction
US7914989B2 (en) Capture moieties for nucleic acids and uses thereof
US9528148B2 (en) Multiplex targeted amplification using flap nuclease
EP1358350B1 (en) Polynucleotide sequence assay
Dobosy et al. RNase H-dependent PCR (rhPCR): improved specificity and single nucleotide polymorphism detection using blocked cleavable primers
US6221603B1 (en) Rolling circle amplification assay for nucleic acid analysis
AU2005230833B2 (en) Quantitative amplification with a labeled probe and 3' to 5' exonuclease activity
US7846657B2 (en) Detection of target nucleotide sequences using ligation assays with improved oligonucleotide probe pairs
KR101958659B1 (en) Dna polymerases with increased mutation specific amplification
WO2003020983A1 (en) Allele specific pcr for genotyping
KR101958660B1 (en) Pcr buffer compositions for increasing activity of dna polymerases with increased mutation specificity
US20090181401A1 (en) Detection format for hot start real time polymerase chain reaction
US20240076633A1 (en) Pcr buffer composition for increasing activity of dna polymerase with increased gene mutation specificity
US20050277134A1 (en) Method for amplifying nucleic acid and analysis of single-nucleotide polymorphism using the same
US7211382B2 (en) Primer extension using modified nucleotides
Borodina et al. Ligation detection reaction-TaqMan procedure for single nucleotide polymorphism detection on genomic DNA
WO2005026389A2 (en) Ligation-based method of analysis of single nucleotide polymorphisms on genomic dna
US9617588B2 (en) Enzyme mixture
US20030235827A1 (en) Methods and compositions for monitoring primer extension and polymorphism detection reactions
US20060051749A1 (en) Polymorphism and haplotype scoring by differential amplification of polymorphisms
Banér Genetic Analyses using Rolling Circle or PCR Amplified Padlock Probes

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION